Synthesis, pharmacological characterization, and structure - Activity relationship studies of small molecular agonists for the orphan GPR88 receptor

Article abstract of DOI:10.1021/cn500082p

GPR88 is an orphan G-protein-coupled receptor (GPCR) enriched in the striatum. Genetic deletion and gene expression studies have suggested that GPR88 plays an important role in the regulation of striatal functions and is implicated in psychiatric disorder

Full text of DOI:10.1021/cn500082p

Research Article
pubs.acs.org/chemneuro
Synthesis, Pharmacological Characterization, and Structure−Activity
Relationship Studies of Small Molecular Agonists for the Orphan
GPR88 Receptor
Chunyang Jin,*,† Ann M. Decker,† Xi-Ping Huang,‡ Brian P. Gilmour,† Bruce E. Blough,† Bryan L. Roth,‡
Yang Hu,§ Joseph B. Gill,§ and X. Peter Zhang§
†Center for Drug Discovery, Research Triangle Institute, Research Triangle Park, North Carolina 27709, United States
‡National Institute of Mental Health Psychoactive Drug Screening Program, Department of Pharmacology and Division of Chemical
Biology and Medicinal Chemistry, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599, United
States
§Department of Chemistry, University of South Florida, Tampa, Florida 33620, United States
S
* Supporting Information
ABSTRACT: GPR88 is an orphan G-protein-coupled receptor (GPCR) enriched in the
striatum. Genetic deletion and gene expression studies have suggested that GPR88 plays
an important role in the regulation of striatal functions and is implicated in psychiatric
disorders. The signal transduction pathway and receptor functions of GPR88, however,
are still largely unknown due to the lack of endogenous and synthetic ligands. In this
paper, we report the synthesis of a GPR88 agonist 2-PCCA and its pure diastereomers,
which were functionally characterized in both transiently and stably expressing GPR88
HEK293 cells. 2-PCCA inhibited isoproterenol-stimulated cAMP accumulation in a
concentration-dependent manner in cells expressing GPR88 but not in the control cells,
suggesting that the observed cAMP inhibition is mediated through GPR88 and that
GPR88 is coupled to Gαi. 2-PCCA did not induce calcium mobilization in GPR88 cells, indicating no Gαq-mediated response. A
structure−activity relationship (SAR) study of 2-PCCA was also conducted to explore the key structural features for GPR88
agonist activity.
KEYWORDS: Orphan GPR88, agonists, 2-PCCA
PR88 is an orphan G-protein-coupled receptor, which
was originally identified as a striatum-specific receptor
and is a promising drug target for treating basal ganglia-
associated disorders.
G
(designated Strg/GPR88),1 though it is also expressed in other
brain regions, including the cerebral cortex, amygdala, and
hypothalamus.2 In the striatum, GPR88 is highly expressed in
both D1 and D2 receptor-expressing medium spiny neurons
(MSNs),2b,3 suggesting the receptor may play a role in
regulating dopaminergic activity. GPR88 knockout mice
demonstrated disrupted prepulse inhibition of the startle
response, a phenotype of schizophrenia, and exhibited D2
receptors hypersensitivity (as evidenced by increased sensitivity
to apomorphine-induced climbing and stereotypy, and amphet-
amine-stimulated locomotor activity).4 In another study of
GPR88 knockout mice,3,5 the animals exhibited increased
locomotion, and impaired motor coordination and cue-based
learning. GPR88 re-expression normalized these impaired
behaviors, suggesting that GPR88 dysfunction may contribute
to abnormal behaviors observed in neurological and psychiatric
diseases.3 In line with these findings from GPR88 knockout
studies, transcriptional profiling studies have revealed GPR88
gene expression is altered by treatment or conditions related to
schizophrenia,6 bipolar disorder,7 depression,8 and drug
addiction.9 Taken together, these studies suggest that GPR88
plays an important role in the regulation of striatal functions
In order to elucidate the biological function of GPR88,
selective agonists are required. Recently, a series of surrogate
agonists of GPR88 have been reported in the patent literature
and were suggested to activate GPR88 coupling to Gαi
pathways.10 However, the function and structure−activity
relationship (SAR) relative to these compounds are unclear.
In this paper, we report the synthesis of a GPR88 ligand 2-
PCCA [(1R*,2R*)-2-(pyridin-2-yl)cyclopropanecarboxylic acid
((2S,3S)-2-amino-3-methylpentyl)-(4′-propylbiphenyl-4-yl)-
amide (1); Figure 1] and its pure (1R,2R)- and (1S,2S)-
diastereomers (2 and 3, respectively), which were functionally
characterized in the GPR88 cell-based cAMP assays. A series of
2-PCCA analogues (4a−i, 5a−e, 6a, and 6b; Figure 2) were
also synthesized and examined to explore the SAR of this
chemical scaffold at GPR88.
Received: April 14, 2014
Revised: May 2, 2014
© XXXX American Chemical Society
A
dx.doi.org/10.1021/cn500082p | ACS Chem. Neurosci. XXXX, XXX, XXX−XXX

ACS Chemical Neuroscience
Research Article
Figure 1. Structures of 2-PCCA (1), 2, and 3.
Figure 2. 2-PCCA analogues.
thesis of (1R,2R)-14 was accomplished starting from the
preparation of pure enantiomer (1R,2R)-2-(pyridin-2-yl)-
cyclopropanecarboxylic acid ((1R,2R)-10). Thus, asymmetric
cyclopropanation of 8 using the known chiral porphyrin catalyst
[Co(3,5-DitBu-ChenPhyrin)]11 afforded the tert-butyl ester
(1R,2R)-9 in 97% ee, as determined by chiral HPLC analysis.
The chiral porphyrin Co(II) catalysts have been well studied in
the asymmetric cyclopropanation of olefins using diazoacetates
to give the corresponding cyclopropanes with high diaster-
eoselectivity and enantioselectivity.11 Assignment of the
absolute configuration of (1R,2R)-9 was made based on an
analogy to the known (1R,2R)-2-phenyl-1-cyclopropanecarbox-
ylic acid tert-butyl ester11a synthesized using the same chiral
porphyrin catalyst. Acidic hydrolysis of (1R,2R)-9 led to acid
(1R,2R)-10, which was then coupled with amine 13 to provide
(1R,2R)-14 in 40% yield over three steps. To obtain the pure
diastereomer (1S,2S)-14, the mixture 14 was separated by
HPLC using a ChiralPak IA column to afford (1R,2R)-14 and
(1S,2S)-14 in 40% and 39% yield, respectively. Suzuki coupling
of (1R,2R)-14 and (1S,2S)-14 with 4-propylphenylboronic acid,
followed by removal of the Boc protecting group with HCl gave
2 and 3, in 80% and 81% yield, respectively.
CHEMISTRY
■
2-PCCA (1) and the 4-substituted bisphenyl analogues 4a−i
were synthesized by a known procedure,10b outlined in Scheme
1, with some modifications. A diastereomeric mixture was first
synthesized to characterize the GPR88 signaling pathways.
Asymmetric synthesis of both pure diastereomers 2 and 3 of 2-
PCCA was conducted later to determine which isomer is more
active. Cyclopropanation of 2-vinylpyridine (8) with tert-butyl
diazoacetate under catalytic conditions led to tert-butyl ester 9,
which was then treated with 4 M HCl in dioxane to give the
racemic (1R*,2R*)-2-(pyridin-2-yl)cyclopropanecarboxylic acid
(10) in 56% yield. Reductive amination of aldehyde 12,
prepared by Dess-Martin oxidation of commercially available
(−)-(2S,3S)-N-Boc-2-amino-3-methyl-1-pentanol with 4-bro-
moaniline (11) afforded amine 13 in 75% yield. With both
building blocks available, amide 14 was synthesized in 72%
yield by converting acid 10 into the corresponding acid
chloride, followed by reaction with amine 13. Suzuki coupling
of 14 with an appropriate arylboronic acid under microwave
conditions gave intermediates 15a−j in the range of 65−96%
yields. Removal of the Boc protecting group with 4 M HCl in
dioxane provided 1 and 4a−i in 90−98% yields. Compounds 1
and 4a−i were determined to be 1:1 diastereomeric mixtures by
1H NMR and HPLC analyses.
Compounds 5a−e were synthesized using the procedure,
outlined in Scheme 3, analogous to that used to prepare 1.
Reductive amination of an appropriate aldehyde 17a−e with 4-
bromoaniline (11) or 4-(4′-propylphenyl)aniline (16) afforded
amine 18a−e in 50−86% yields. Amide formation with the acid
chloride, prepared from the racemic 10, gave 19a−e in 53−60%
yields. Suzuki coupling of 19a, 19b, and 19e with 4-
propylphenylboronic acid yielded 53−80% of 20a, 20b, and
Synthesis of pure diastereomers 2 and 3 of 2-PCCA is
described in Scheme 2. The key intermediate 14, prepared from
enantiomerically pure (−)-(2S,3S)-N-Boc-2-amino-3-methyl-1-
pentanol as described in Scheme 1, is a 1:1 mixture of (1R,2R)-
and (1S,2S)-diastereomers differentiating at the configuration
of the trans-substituted cyclopropane ring. Asymmetric syn-
B
dx.doi.org/10.1021/cn500082p | ACS Chem. Neurosci. XXXX, XXX, XXX−XXX

ACS Chemical Neuroscience
Research Article
a
Scheme 1
a
Reagents: (a) tert-butyl diazoacetate, 5,10,15,20-tetraphenyl-21H,23H-porphine cobalt(II), toluene, 80 °C, 2 h; (b) 4 M HCl/dioxane, DCM, rt,
overnight; (c) NaBH(OAc)3, 1,2-dichloroethane, rt, overnight; (d) 10/oxalyl chloride/DCM/40 °C/2 h, concentrated, then 13/Et3N/DCM, rt,
overnight; (e) arylboronic acid, Pd(dppf)Cl2·DCM, K3PO4, DME/H2O (3:1), microwave, 160 °C, 6 min; (f) 4 M HCl/dioxane, DCM, rt, 6 h.
20e. Deprotection of the Boc group furnished 5a−e as 1:1
diastereomeric mixtures in 92−98% yields.
manner. 2-PCCA inhibited ISO-induced cAMP formation with
a pEC50 value of 6.06 (EC50 = 877 nM) in GPR88 cells but not
in the control cells transiently transfected with the biosensor,
demonstrating that 2-PCCA activates GPR88-mediated Gαi
Synthesis of compounds 6a and 6b started with the reaction
of amine 13 with (1R,2R)-2-phenyl-1-cyclopropanecarboxylic
acid12 and 2-pyridylacetic acid (Scheme 4), respectively. The
resulting amides 21a and 21b were coupled with 4-
propylphenylboronic acid, followed by HCl treatment to
provide 6a and 6b in 55% and 33% overall yield, respectively.
All synthesized compounds were >95% pure as determined by
HPLC analyses. The 1H NMR spectra of the target compounds
were in agreement with the assigned structures.
signaling (Figure 3). In addition, the (1R,2R)-isomer 2 (EC50
=
373 nM) is approximately 5-fold more potent than the (1S,
2S)-isomer 3. Furthermore, 2-PCCA did not induce calcium
mobilization measured by the fluorescent imaging plate reader
(FLIPR) calcium assay13b,14 in HEK293T/GPR88 cells (data
not shown), indicating that GPR88 is likely not coupled to Gαq
proteins in our assay systems.
To further characterize the GPR88 in vitro functions and
explore the key structural features of 2-PCCA agonist activity,
HEK293 cells stably expressing the human GPR88 receptor
and the GloSensor-22F cAMP construct were established. In
the stable GPR88-22F cells, 2-PCCA and its pure diastereomer
RESULTS AND DISCUSSION
■
Despite emerging pharmacological implications of the orphan
GPR88 receptor, little is known regarding its downstream
signaling pathways, as identification of endogenous and
synthetic ligands has been elusive. Results from the patent
literature10 indicated that GPR88 couples to Gαi proteins and
thereby inhibits cAMP production. To develop an appropriate
cell based assay system to support drug discovery for the
GPR88 receptor, we initially transiently cotransfected HEK
293T cells with the human GPR88 cDNA and a luminescent
cAMP biosensor and determined both Gαs and Gαi
activations.13 2-PCCA (1) produced no measurable increases
in cAMP levels at concentrations up to 30 μM. As a positive
control, isoproterenol (ISO) activated the endogenous β2
adrenergic receptors expressed in HEK293T cells and greatly
stimulated cAMP production in a concentration-dependent
2 had pEC50 values of 6.04 (EC50 = 911 nM) and 6.22 (EC50
=
603 nM), respectively. To explore the SAR of 2-PCCA,
substitution effects of the bisphenyl moiety were first examined.
As seen in Table 1, unsubstituted analogue 4a was less potent
than 2-PCCA. The 4-position tolerated small to medium size of
alkyl substitutions with the methyl analogue 4b (EC50 = 845
nM) and cyclohexyl analogue 4e (EC50 = 746 nM) being the
most potent compounds in the series. Replacing the methyl
group with an electron-withdrawing trifluoromethyl group (4f)
markedly reduced activity. The addition of a fluoro or chloro
group to the 4-position led to 4g and 4h, respectively, resulting
in even lower potency. Somewhat surprisingly, the 4-acetyl
C
dx.doi.org/10.1021/cn500082p | ACS Chem. Neurosci. XXXX, XXX, XXX−XXX

ACS Chemical Neuroscience
Research Article
a
Scheme 2
a
Reagents: (a) tert-butyl diazoacetate, 1 mol % Co(3,5-di-t-Bu-ChenPhyrin) catalyst, DMAP, toluene, rt, 48 h; (b) 4 M HCl/dioxane, DCM, rt,
overnight; (c) (1R,2R)-10/oxalyl chloride/DCM/40 °C/2 h, concentrated, then 13/ Et3N/DCM, rt, overnight; (d) HPLC separation; (e) 4-
propylphenylboronic acid, Pd(dppf)Cl2·DCM, K3PO4, DME/H2O (3:1), microwave, 160 °C, 6 min; (f) 4 M HCl/dioxane, DCM, rt, 6 h.
a
Scheme 3
a
Reagents: (a) NaBH(OAc)3, 1,2-dichloroethane, rt, overnight; (b) 10/oxalyl chloride/DCM/40 °C/2 h, concentrated, then 18a−e/Et3N/DCM, rt,
overnight; (c) 4-propylphenylboronic acid, Pd(dppf)Cl2·DCM, K3PO4, DME/H2O (3:1), microwave, 160 °C, 6 min; (d) 4 M HCl/dioxane, DCM,
rt, 6 h.
analogue 4i possessed a similar potency (EC50 = 923 nM) at
GPR88 relative to 2-PCCA.
Investigation of the substituted ethylamine moiety of 2-
PCCA (Table 2) showed that hydrophobic substitutions were
well tolerated. The trend of increased potency with large
substituents (5a−e) at the ethylamine moiety suggests that a
hydrophobic pocket may be present in the GPR88 receptor. A
limited examination of the amide carbonyl groups observed that
the pyridyl group in 2-PCCA could be replaced with a phenyl
group (6a) while causing only a slight decrease in potency.
D
dx.doi.org/10.1021/cn500082p | ACS Chem. Neurosci. XXXX, XXX, XXX−XXX

ACS Chemical Neuroscience
Research Article
a
Scheme 4
a
Reagents: (a) 21a: (1R, 2R)-2-phenyl-1-cyclopropanecarboxylic acid/SOCl2/reflux, overnight, concentrated, then 13/Et3N/DCM, rt, overnight;
21b: 2-pyridylacetic acid, HBTU, Et3N, MeCN, rt, overnight; (b) 4-propylphenylboronic acid, Pd(dppf)Cl2·DCM, K3PO4, DME/H2O (3:1),
microwave, 160 °C, 6 min; (c) 4 M HCl/dioxane, DCM, rt, 6 h.
Figure 3. HEK 293T cells were transiently transfected with GPR88 and GloSensor cAMP construct (A) or GloSensor cAMP only (B). 2-PCCA (1),
2, and 3 inhibited isoproterenol-induced cAMP production in GPR88 cells, but not in the control cells. The data are the means of quadruplicate
measurements with standard deviation shown as error bars and are representative of at least three independent experiments.
However, replacement of the cyclopropane moiety with a
methylene group (6b) resulted in a loss of activity, indicating
the central linker of the aromatic and carbonyl moieties is
critical for GPR88 recognition.
METHODS
■
Chemistry. General Methods. Melting points were determined
using a MEL-TEMP II capillary melting point apparatus and are
uncorrected. Nuclear magnetic resonance (1H NMR and 13C NMR)
spectra were obtained on a Bruker Avance DPX-300 MHz NMR
spectrometer. Chemical shifts are reported in parts per million (ppm)
with reference to internal solvent. 13C NMR data of diastereomeric
mixtures were not reported due to the complicity of the spectra. Mass
spectra (MS) were run on a PerkinElmer Sciex API 150 EX mass
spectrometer. HRMS spectra were run on a Waters Synapt G2 HDMS
Q-TOF mass spectrometer, using electrospray ionization in positive
ion mode. Optical rotations were measured on an AutoPol III
polarimeter, purchased from Rudolf Research. Analytical thin-layer
chromatography (TLC) was carried out using EMD silica gel 60 F254
TLC plates. TLC visualization was achieved with a UV lamp or in an
iodine chamber. Flash column chromatography was done on a
CombiFlash Companion system using Isco prepacked silica gel
columns. Unless otherwise stated, reagent-grade chemicals were
obtained from commercial sources and were used without further
purification. All moisture- and air-sensitive reactions and reagent
transfers were carried out under dry nitrogen.
CONCLUSIONS
■
In summary, we demonstrated that GPR88 couples to the Gαi
subunits, and is activated by 2-PCCA in both transient and
stable GPR88 expressing cells. In an effort to determine the key
structural features for 2-PCCA agonist activity, we designed and
synthesized a series of 2-PCCA analogues 4a−i, 5a−e, 6a, and
6b. Further pharmacological evaluation of the (1R,2R)-isomer 2
and phenyl analogue 6a, including receptor specificity and in
vivo behavioral studies, are in progress. These studies will
facilitate the identification of highly potent, selective ligands for
GPR88 and the understanding of its physiological functions in
vivo.
E
dx.doi.org/10.1021/cn500082p | ACS Chem. Neurosci. XXXX, XXX, XXX−XXX

ACS Chemical Neuroscience
Research Article
1
brown oil: H NMR (300 MHz; CDCl3) δ 8.44 (d, J = 6.0 Hz, 1H),
7.56 (td, J = 6.0, 3.0 Hz, 1H)), 7.23 (t, J = 6.0 Hz, 1H), 7.11−6.93 (m,
1H), 2.51 (ddd, J = 9.0, 6.0, 3.0 Hz, 1H), 2.16 (ddd, J = 9.0, 6.0, 3.0
Hz, 1H), 1.57−1.48 (m, 2H), 1.45 (s, 9H); 13C NMR (75 MHz;
CDCl3) δ 172.6, 159.3, 149.4, 135.9, 123.3, 121.1, 80.5, 28.2, 26.8,
25.4, 17.2; MS (ESI) m/z 220.4 [M + H]+.
Table 1. Structures and Activities of Compounds 1, 2, and
4a−i
( )-(1R*,2R*)-2-(Pyridin-2-yl)cyclopropanecarboxylic Acid Hy-
drochloride (10). To a solution of 9 (0.80 g, 3.65 mmol) in CH2Cl2
(10 mL) was added 4 M HCl in dioxane (3 mL), and the reaction was
stirred at room temperature overnight. The solvent was removed
under reduced procedure. The residue was triturated with CH2Cl2/
Et2O to afford 10 (0.60 g, 81%) as a greenish solid: mp 141−143 °C;
1H NMR (300 MHz; DMSO-d6) δ 12.00 (br s, 1H), 8.67 (dd, J = 6.0,
3.0 Hz, 1H), 8.30 (td, J = 6.0, 3.0 Hz, 1H), 7.81−7.68 (m, 2H), 2.90
(ddd, J = 9.0, 6.0, 3.0 Hz, 1H), 2.33 (ddd, J = 9.0, 6.0, 3.0 Hz, 1H),
1.80−1.60 (m, 2H); 13C NMR (75 MHz; DMSO-d6) δ 172.5, 156.1,
134.5, 143.0, 123.8, 123.4, 25.0, 23.2, 17.3; MS (ESI) m/z 164.4 [M +
H]+.
a
b
compd
R
pEC50 (EC50, nM)
2-PCCA (1)
Pr
6.04 0.06 (911)
6.22 0.10 (603)
2
Pr
tert-Butyl {(2S,3S)-1-[(4-Bromophenyl)amino]-3-methylpentan-2-
yl}carbamate (13). To a solution of (−)-(2S,3S)-N-Boc-2-amino-3-
methyl-1-pentanol (2.17 g, 10.0 mmol) in water-saturated CH2Cl2 (10
mL) at room temperature was added Dess-Martin reagent (8.90 g,
21.0 mmol), and the reaction was stirred for 1 h. Additional water-
saturated CH2Cl2 (5 mL) was added every 15 min during the reaction
time. The mixture was diluted with Et2O (100 mL) and poured into a
solution of Na2S2O3 (17 g) in 80% saturated NaHCO3 (100 mL).
After stirring for 10 min, the layers were separated and the aqueous
layer was extracted with Et2O (100 mL). The combined organic layers
were washed with ice-cold saturated NaHCO3 (30 mL) and water (30
mL). The solution was dried (Na2SO4) and concentrated under
reduced pressure to give the crude aldehyde 12. To a solution of 4-
bromoaniline (11) (1.72 g, 10.0 mmol) in dichloroethane (60 mL)
was added the above crude aldehyde, followed by NaBH(OAc)3 (4.24
g, 20.0 mmol). The mixture was stirred at room temperature
overnight. Saturated NaHCO3 (20 mL) was added, and the layers
were separated. The aqueous layer was extracted with CH2Cl2 (2 × 30
mL). The combined organic layers were washed with brine (3 × 30
mL), dried (Na2SO4) and concentrated under reduced pressure. Flash
column chromatography of the crude product on silica gel using 0−
4a
4b
4c
4d
4e
4f
H
5.48 0.08 (3321)
6.07 0.14 (845)
5.70 0.08 (1989)
5.74 0.06 (1803)
6.13 0.13 (746)
5.49 0.08 (3266)
Me
Et
i-Bu
cyclohexyl
CF3
c
4g
4h
4i
fluoro
chloro
acetyl
NA
c
NA
6.03 0.05 (923)
a
b
All compounds were tested as the HCl salt. pEC50 values are means
standard error of at least three independent experiments performed
in duplicate. EC50 > 10 μM, tested in two independent experiments
performed in duplicate.
c
Table 2. Structures and Activities of Compounds 5a−e, 6a,
and 6b
30% EtOAc in hexanes afforded 13 (2.78 g, 75%) as a white solid: mp
1
103−105 °C; [α]23 +11.4° (c 0.52, CH3OH); H NMR (300 MHz;
D
CDCl3) δ 7.24 (d, J = 9.0 Hz, 2H), 6.45 (d, J = 9.0 Hz, 2H), 4.52 (d, J
= 9.0 Hz, 1H), 4.20 (br s, 1H), 3.82−3.65 (m, 1H), 3.30−3.14 (m,
1H), 3.05−2.89 (m, 1H), 1.60−1.47 (m, 1H), 1.44 (s, 9H), 1.23−1.10
(m, 1H), 0.95 (d, J = 6.0 Hz, 3H), 0.95 (t, J = 7.5 Hz, 3H); 13C NMR
(75 MHz; CDCl3) δ 154.9, 145.7, 130.1, 112.4, 106.9, 77.9, 52.9, 45.0,
35.7, 26.6, 23.6, 13.8, 9.9; MS (ESI) m/z 371.3 [M + H]+ (79Br), 373.3
[M + H]+ (81Br).
a
b
compd
R1
R2
pEC50 (EC50, nM)
6.04 0.06 (911)
2-PCCA (1)
tert-Butyl [(2S,3S)-1-{4-Bromophenyl-[(1R*,2R*)-2-(pyridin-2-yl)-
cyclopropanecarbonyl]amino}-3-methylpentan-2-yl]carbamate
(14). To a solution of 10 (0.40 g, 2.0 mmol) in CH2Cl2 (20 mL) at
room temperature was added oxalyl chloride (0.35 mL, 4.0 mmol) and
DMF (50 μL). The mixture was stirred at 40 °C for 2 h and then
cooled to room temperature and concentrated under reduced pressure.
The residue was dissolved in CH2Cl2 (20 mL) and treated with 13
(0.74 g, 2.0 mmol) and Et3N (1.1 mL, 8.0 mmol). The resulting
solution was stirred at room temperature overnight. Saturated
NaHCO3 (10 mL) was added, and the layers were separated. The
aqueous layer was extracted with CH2Cl2 (3 × 10 mL). The combined
organic layers were washed with brine (3 × 20 mL), dried (Na2SO4)
and concentrated under reduced pressure. Flash column chromatog-
raphy of the crude product on silica gel using 0−25% EtOAc in
hexanes afforded 14 (0.74 g, 72%, 1:1 diastereomeric mixture) as a
light yellow foam: 1H NMR (300 MHz; CDCl3) δ 8.30 (d, J = 6.0 Hz,
1H), 7.58−7.34 (m, 3H), 7.22−6.98 (m, 4H), 4.96 (d, J = 9.0 Hz,
1H), 4.45−4.25 (m, 1H), 3.80−3.78 (m, 1H), 3.21−3.06 (m, 1H),
2.71−2.62 (m, 0.5 H), 2.58−2.48 (m, 0.5 H), 1.98−1.86 (m, 1H),
1.75−1.62 (m, 1H), 1.60−1.35 (m, 3H), 1.45 and 1.40 (2s, 9H),
1.15−1.02 (m, 1H), 0.92−0.80 (m, 6H); MS (ESI) m/z 516.7 [M +
H]+ (79Br), 518.6 [M + H]+ (81Br).
5a
5b
5c
5d
5e
6a
H
5.27 0.12 (5330)
5.42 0.12 (3821)
5.80 0.09 (1602)
6.00 0.21 (994)
6.05 0.19 (898)
5.90 0.05 (1250)
Me
i-Pr
i-Bu
PhCH2
(1R,2R)-2-phenyl-
cyclopropan-1-yl
c
6b
(pyridin-2-yl)methyl
NA
a
b
All compounds were tested as the HCl salt. pEC50 values are means
standard error of at least three independent experiments performed
in duplicate. EC50 > 10 μM
c
( )-tert-Butyl (1R*,2R*)-2-(pyridin-2-yl)cyclopropanecarboxylate
(9). A solution of 2-vinylpyridine (8) (0.58 mL, 5.4 mmol), tert-butyl
diazoacetate (0.88 mL, 6.4 mmol), and 5,10,15,20-tetraphenyl-
21H,23H-porphine cobalt(II) (72 mg, 0.11 mmol) in toluene (25
mL) was heated in a sealed tube at 80 °C for 2 h. After cooling to
room temperature, the mixture was concentrated under reduced
pressure. Flash column chromatography of the crude product on silica
gel using 0−30% EtOAc in hexanes afforded 9 (0.82 g, 69%) as a
F
dx.doi.org/10.1021/cn500082p | ACS Chem. Neurosci. XXXX, XXX, XXX−XXX

ACS Chemical Neuroscience
Research Article
tert-Butyl [(2S,3S)-1-{(4′-Propylbiphenyl-4-yl)-[(1R*,2R*)-2-(pyri-
din-2-yl)cyclopropanecarbonyl]amino}-3-methylpentan-2-yl]-
carbamate (15a). A mixture of 14 (0.48 g, 0.92 mmol), 4-
propylphenylboronic acid (0.25 g, 1.4 mmol), Pd(dppf)Cl2·CH2Cl2
(70 mg, 0.092 mmol), and K3PO4 (0.58 g, 2.7 mmol) in
dimethoxyethane (10.5 mL) and water (3.5 mL) was heated in a
sealed vessel by microwave irradiation at 160 °C for 6 min. The
resulting mixture was poured into 1 N NaOH solution (30 mL) and
extracted with CH2Cl2 (3 × 30 mL). The combined organic layers
were dried (Na2SO4) and concentrated under reduced pressure. Flash
column chromatography of the crude product on silica gel using 0−
20% EtOAc in hexanes afforded 15a (0.49 g, 96%, 1:1 diastereomeric
(m, 1H), 7.58−7.40 (m, 5H), 7.32−7.12 (m, 5H), 7.02−6.92 (m, 1H),
5.15−5.05 (m, 1H), 4.50−4.36 (m, 1H), 3.88−3.68 (m, 1H), 3.26−
3.13 (m, 1H), 2.75−2.64 (m, 0.5 H), 2.60−2.48 (m, 1.5H), 2.05−1.71
(m, 7H), 1.69−1.25 (m, 8H), 1.47 and 1.43 (2s, 9H), 1.17−1.00 (m,
1H), 0.96−0.80 (m, 6H); MS (ESI) m/z 596.9 [M + H]+.
tert-Butyl [(2S,3S)-1-{(4′-Trifluoromethylbiphenyl-4-yl)-
[(1R*,2R*)-2-(pyridin-2-yl)cyclopropanecarbonyl]amino}-3-methyl-
pentan-2-yl]carbamate (15g). The procedure for 15a was followed
using 30 mg (0.058 mmol) of 14 and 17 mg (0.087 mmol) of 4-
trifluoromethylphenylboronic acid to give 25 mg (74%) of 15g as a 1:1
1
diastereomeric mixture: H NMR (300 MHz; CDCl3) δ 8.30−8.22
(m, 1H), 7.72−7.40 (m, 7H), 7.38−7.16 (m, 3H), 7.02−6.93 (m, 1H),
5.13−5.02 (m, 1H), 4.50−4.38 (m, 1H), 3.84−3.65 (m, 1H), 3.28−
3.15 (m, 1H), 2.76−2.65 (m, 0.5 H), 2.61−2.48 (m, 0.5H), 2.08−1.96
(m, 1H), 1.76−1.55 (m, 1H), 1.54−1.37 (m, 3H), 1.47 and 1.43 (2s,
9H), 1.18−1.00 (m, 1H), 0.94−0.78 (m, 6H); MS (ESI) m/z 582.7
[M + H]+.
1
mixture) as a white foam: H NMR (300 MHz; CDCl3) δ 8.28−8.22
(m, 1H), 7.58−7.38 (m, 5H), 7.32−7.13 (m, 5H), 7.03−6.96 (m, 1H),
5.12−5.05 (m, 1H), 4.48−4.36 (m, 1H), 3.85−3.56 (m, 1H), 3.24−
3.13 (m, 1H), 2.71−2.50 (m, 3H), 2.05−1.95 (m, 1H), 1.75−1.58 (m,
3H), 1.51−1.38 (m, 3H), 1.47 and 1.43 (2s, 9H), 1.56−1.40 (m, 1H),
0.97 (t, J = 7.5 Hz, 3H), 0.92−0.80 (m, 6H); MS (ESI) m/z 557.0 [M
+ H]+.
tert-Butyl [(2S,3S)-1-{(4′-Fluorobiphenyl-4-yl)-[(1R*,2R*)-2-(pyri-
din-2-yl)cyclopropanecarbonyl]amino}-3-methylpentan-2-yl]-
carbamate (15h). The procedure for 15a was followed using 30 mg
(0.058 mmol) of 14 and 12 mg (0.087 mmol) of 4-fluorophenylbor-
onic acid to give 20 mg (74%) of 15h as a 1:1 diastereomeric mixture:
1H NMR (300 MHz; CDCl3) δ 8.30−8.22 (m, 1H), 7.56−7.48 (m,
4H), 7.30−7.18 (m, 6H), 7.02−7.92 (m, 1H), 5.12−5.05 (m, 1H),
4.52−4.38 (m, 1H), 3.82−3.65 (m, 1H), 3.25−3.12 (m, 1H), 2.76−
2.65 (m, 0.5 H), 2.61−2.48 (m, 0.5H), 2.08−1.95 (m, 1H), 1.78−1.55
(m, 1H), 1.54−1.37 (m, 3H), 1.47 and 1.43 (2s, 9H), 1.18−1.00 (m,
1H), 0.95−0.80 (m, 6H); MS (ESI) m/z 532.5 [M + H]+.
tert-Butyl [(2S,3S)-1-{(4′-Chlorobiphenyl-4-yl)-[(1R*,2R*)-2-(pyri-
din-2-yl)cyclopropanecarbonyl]amino}-3-methylpentan-2-yl]-
carbamate (15i). The procedure for 15a was followed using 30 mg
(0.058 mmol) of 14 and 14 mg (0.087 mmol) of 4-chlorophenylbor-
onic acid to give 22 mg (74%) of 15i as a 1:1 diastereomeric mixture:
1H NMR (300 MHz; CDCl3) δ 8.30−8.21 (m, 1H), 7.55−7.36 (m,
6H), 7.30−7.15 (m, 4H), 7.02−7.95 (m, 1H), 5.10−5.00 (m, 1H),
4.50−4.35 (m, 1H), 3.80−3.62 (m, 1H), 3.26−3.15 (m, 1H), 2.76−
2.65 (m, 0.5 H), 2.61−2.48 (m, 0.5H), 2.08−1.95 (m, 1H), 1.75−1.55
(m, 1H), 1.54−1.37 (m, 3H), 1.47 and 1.42 (2s, 9H), 1.16−1.00 (m,
1H), 0.95−0.80 (m, 6H); MS (ESI) m/z 548.5 [M + H]+.
tert-Butyl [(2S,3S)-1-{(4′-Acetylbiphenyl-4-yl)-[(1R*,2R*)-2-(pyri-
din-2-yl)cyclopropanecarbonyl]amino}-3-methylpentan-2-yl]-
carbamate (15j). The procedure for 15a was followed using 30 mg
(0.058 mmol) of 14 and 14 mg (0.087 mmol) of 4-acetylphenylbor-
onic acid to give 25 mg (76%) of 15j as a 1:1 diastereomeric mixture:
1H NMR (300 MHz; CDCl3) δ 8.30−8.21 (m, 1H), 8.06−7.98 (m,
2H), 7.68−7.48 (m, 5H), 7.38−7.15 (m, 3H), 7.02−7.93 (m, 1H),
5.10−5.00 (m, 1H), 4.50−4.36 (m, 1H), 3.80−3.62 (m, 1H), 3.28−
3.15 (m, 1H), 2.75−2.65 (m, 0.5 H), 2.64 (s, 3H), 2.61−2.48 (m,
0.5H), 2.08−1.95 (m, 1H), 1.76−1.55 (m, 1H), 1.54−1.37 (m, 3H),
1.47 and 1.43 (2s, 9H), 1.16−0.98 (m, 1H), 0.92−0.78 (m, 6H); MS
(ESI) m/z 557.2 [M + H]+.
(1R*,2R*)-2-(Pyridin-2-yl)cyclopropanecarboxylic Acid [(2S,3S)-2-
Amino-3-methylpentyl]-(4′-propylbiphenyl-4-yl)amide Dihydro-
chloride (1). A solution of 15a (150 mg, 0.27 mmol) and 4 M HCl
in dioxane (2 mL) in CH2Cl2 (5 mL) was stirred at room temperature
for 6 h. The solvent was removed under reduced pressure. The
resulting residue was triturated with Et2O to give 1 (135 mg, 95%, 1:1
diastereomeric mixture) as a white solid: 1H NMR (300 MHz;
CD3OD) δ 8.66−8.54 (m, 1H), 8.37−8.23 (m, 1H), 7.82−7.44 (m,
8H), 7.32−7.22 (m, 2H), 4.43 (dd, J = 15.0, 9.0 Hz, 0.5H), 4.28 (dd, J
= 15.0, 9.0 Hz, 0.5H), 3.82 (d, J = 15.0 Hz, 0.5H), 3.68 (d, J = 15.0 Hz,
0.5H), 3.46−3.35 (m, 1H), 3.11−3.02 (m, 0.5H), 3.00−2.90 (m,
0.5H), 2.62 (t, J = 7.5 Hz, 2H), 2.22−2.08 (m, 1H), 2.02−1.88 (m,
1H), 1.87−1.62 (m, 4H), 1.50−1.12 (m, 2H), 1.02−0.78 (m, 9H);
HRMS (ESI) calcd. for C30H37N3O [M + H]+: 456.3009. Found:
456.3020.
tert-Butyl [(2S,3S)-1-{(Biphenyl-4-yl)-[(1R*,2R*)-2-(pyridin-2-yl)-
cyclopropanecarbonyl]amino}-3-methylpentan-2-yl]carbamate
(15b). The procedure for 15a was followed using 30 mg (0.058 mmol)
of 14 and 11 mg (0.087 mmol) of phenylboronic acid to give 24 mg
1
(81%) of 15b as a 1:1 diastereomeric mixture: H NMR (300 MHz;
CDCl3) δ 8.28−8.22 (m, 1H), 7.59−7.38 (m, 6H), 7.37−7.14 (m,
5H), 7.12−6.95 (m, 1H), 5.14−5.07 (m, 1H), 4.49−4.36 (m, 1H),
3.85−3.68 (m, 1H), 3.26−3.14 (m, 1H), 2.75−2.66 (m, 0.5 H), 2.60−
2.50 (m, 0.5H), 2.08−1.98 (m, 1H), 1.75−1.66 (m, 0.5H), 1.65−1.57
(m, 0.5H), 1.55−1.36 (m, 3H), 1.47 and 1.43 (2s, 9H), 1.18−1.02 (m,
1H), 0.94−0.80 (m, 6H); MS (ESI) m/z 514.7 [M + H]+.
tert-Butyl [(2S,3S)-1-{(4′-Methylbiphenyl-4-yl)-[(1R*,2R*)-2-(pyri-
din-2-yl)cyclopropanecarbonyl]amino}-3-methylpentan-2-yl]-
carbamate (15c). The procedure for 15a was followed using 30 mg
(0.058 mmol) of 14 and 12 mg (0.087 mmol) of 4-methylphenylbor-
onic acid to give 20 mg (65%) of 15c as a 1:1 diastereomeric mixture:
1H NMR (300 MHz; CDCl3) δ 8.29−8.22 (m, 1H), 7.58−7.38 (m,
5H), 7.37−7.16 (m, 5H), 7.02−6.92 (m, 1H), 5.13−5.06 (m, 1H),
4.48−4.37 (m, 1H), 3.83−3.68 (m, 1H), 3.24−3.12 (m, 1H), 2.73−
2.65 (m, 0.5 H), 2.60−2.50 (m, 0.5H), 2.39 (s, 3H), 2.08−1.96 (m,
1H), 1.76−1.55 (m, 1H), 1.54−1.37 (m, 3H), 1.47 and 1.43 (2s, 9H),
1.17−1.00 (m, 1H), 0.92−0.78 (m, 6H); MS (ESI) m/z 528.7 [M +
H]+.
tert-Butyl [(2S,3S)-1-{(4′-Ethylbiphenyl-4-yl)-[(1R*,2R*)-2-(pyri-
din-2-yl)cyclopropanecarbonyl]amino}-3-methylpentan-2-yl]-
carbamate (15d). The procedure for 15a was followed using 30 mg
(0.058 mmol) of 14 and 13 mg (0.087 mmol) of 4-ethylphenylboronic
1
acid to give 25 mg (80%) of 15d as a 1:1 diastereomeric mixture: H
NMR (300 MHz; CDCl3) δ 8.28−8.23 (m, 1H), 7.58−7.38 (m, 5H),
7.37−7.15 (m, 5H), 7.04−6.95 (m, 1H), 5.15−5.05 (m, 1H), 4.50−
4.37 (m, 1H), 3.85−3.68 (m, 1H), 3.25−3.14 (m, 1H), 2.76−2.66 (m,
2.5 H), 2.60−2.48 (m, 0.5H), 2.10−1.96 (m, 1H), 1.76−1.54 (m, 1H),
1.53−1.37 (m, 3H), 1.47 and 1.43 (2s, 9H), 1.28 (t, J = 7.5 Hz, 3H),
1.17−1.00 (m, 1H), 0.93−0.78 (m, 6H); MS (ESI) m/z 542.6 [M +
H]+.
tert-Butyl [(2S,3S)-1-{(4′-Isobutylbiphenyl-4-yl)-[(1R*,2R*)-2-(pyr-
idin-2-yl)cyclopropanecarbonyl]amino}-3-methylpentan-2-yl]-
carbamate (15e). The procedure for 15a was followed using 30 mg
(0.058 mmol) of 14 and 16 mg (0.087 mmol) of 4-isobutylphenylbor-
onic acid to give 23 mg (77%) of 15e as a 1:1 diastereomeric mixture:
1H NMR (300 MHz; CDCl3) δ 8.28−8.23 (m, 1H), 7.60−7.38 (m,
5H), 7.34−7.15 (m, 5H), 7.04−6.95 (m, 1H), 5.14−5.05 (m, 1H),
4.50−4.36 (m, 1H), 3.86−3.68 (m, 1H), 3.24−3.14 (m, 1H), 2.74−
2.65 (m, 0.5 H), 2.60−2.46 (m, 2.5H), 2.10−1.82 (m, 2H), 1.76−1.54
(m, 1H), 1.53−1.36 (m, 3H), 1.47 and 1.43 (2s, 9H), 1.16−1.00 (m,
1H), 0.98−0.78 (m, 12H); MS (ESI) m/z 570.6 [M + H]+.
tert-Butyl [(2S,3S)-1-{(4′-Cyclohexylbiphenyl-4-yl)-[(1R*,2R*)-2-
(pyridin-2-yl)cyclopropanecarbonyl]amino}-3-methylpentan-2-yl]-
carbamate (15f). The procedure for 15a was followed using 30 mg
(0.058 mmol) of 14 and 18 mg (0.087 mmol) of 4-cyclo-
hexylphenylboronic acid to give 28 mg (81%) of 15f as a 1:1
(1R*,2R*)-2-(Pyridin-2-yl)cyclopropanecarboxylic Acid [(2S,3S)-2-
Amino-3-methylpentyl]-(biphenyl-4-yl)amide Dihydrochloride (4a).
The procedure for 1 was followed using 20 mg (0.039 mmol) of 15b
and 1 mL of 4 M HCl in dioxane to give 17 mg (90%) of 4a as a 1:1
1
1
diastereomeric mixture: H NMR (300 MHz; CDCl3) δ 8.28−8.21
diastereomeric mixture: H NMR (300 MHz; CD3OD) δ 8.28−8.21
G
dx.doi.org/10.1021/cn500082p | ACS Chem. Neurosci. XXXX, XXX, XXX−XXX

ACS Chemical Neuroscience
Research Article
(m, 1H), 7.72−7.52 (m, 5H), 7.48−7.32 (m, 5H), 7.30−7.23 (m, 1H),
7.19−7.10 (m, 1H), 4.40−4.22 (m, 1H), 3.80−3.66 (m, 1H), 3.40−
3.22 (m, 1H), 2.70−2.53 (m, 1H), 2.05−1.90 (m, 1H), 1.84−1.62 (m,
2H), 1.50−1.15 (m, 3H), 0.99 and 0.97 (2d, J = 6.0 Hz, 3H), 0.90−
0.80 (m, 3H); HRMS (ESI) calcd. for C27H31N3O [M + H]+:
414.2541. Found: 414.2540.
(1R*,2R*)-2-(Pyridin-2-yl)cyclopropanecarboxylic Acid [(2S,3S)-2-
Amino-3-methylpentyl]-(4′-chlorobiphenyl-4-yl)amide Dihydro-
chloride (4h). The procedure for 1 was followed using 20 mg
(0.036 mmol) of 15i and 1 mL of 4 M HCl in dioxane to give 18 mg
1
(96%) of 4h as a 1:1 diastereomeric mixture: H NMR (300 MHz;
CD3OD) δ 8.72−8.58 (m, 1H), 8.45−8.35 (m, 1H), 7.90−7.55 (m,
8H), 7.55−7.40 (m, 2H), 4.55−4.42 (m, 0.5H), 4.40−4.25 (m, 0.5H),
3.90−3.60 (m, 1H), 3.50−3.40 (m, 1H), 3.18−3.07 (m, 0.5H), 3.06−
2.96 (m, 0.5H), 2.25−2.10 (m, 1H), 2.08−1.90 (m, 1H), 1.90−1.68
(m, 2H), 1.58−1.12 (m, 2H), 1.10−0.80 (m, 6H); HRMS (ESI) calcd.
for C27H30ClN3O [M + H]+: 448.2150. Found: 448.2162.
(1R*,2R*)-2-(Pyridin-2-yl)cyclopropanecarboxylic Acid [(2S,3S)-2-
Amino-3-methylpentyl]-(4′-methylbiphenyl-4-yl)amide Dihydro-
chloride (4b). The procedure for 1 was followed using 20 mg
(0.038 mmol) of 15c and 1 mL of 4 M HCl in dioxane to give 18 mg
1
(95%) of 4b as a 1:1 diastereomeric mixture: H NMR (300 MHz;
(1R*,2R*)-2-(Pyridin-2-yl)cyclopropanecarboxylic Acid [(2S,3S)-2-
Amino-3-methylpentyl]-(4′-acetylbiphenyl-4-yl)amide Dihydro-
chloride (4i). The procedure for 1 was followed using 20 mg (0.036
mmol) of 15j and 1 mL of 4 M HCl in dioxane to give 17 mg (90%) of
CD3OD) δ 8.68−8.55 (m, 1H), 8.42−8.30 (m, 1H), 7.88−7.40 (m,
8H), 7.30−7.20 (m, 2H), 4.50−4.40 (m, 0.5H), 4.40−4.28 (m, 0.5H),
3.88−3.56 (m, 1H), 3.48−3.38 (m, 1H), 3.12−3.05 (m, 0.5H), 3.05−
2.96 (m, 0.5H), 2.37 (s, 3H), 2.22−2.10 (m, 1H), 2.10−1.88 (m, 1H),
1.87−1.60 (m, 2H), 1.48−1.15 (m, 2H), 1.06−0.80 (m, 6H); HRMS
(ESI) calcd. for C28H33N3O [M + H]+: 428.2696. Found: 428.2701.
(1R*,2R*)-2-(Pyridin-2-yl)cyclopropanecarboxylic Acid [(2S,3S)-2-
Amino-3-methylpentyl]-(4′-ethylbiphenyl-4-yl)amide Dihydrochlor-
ide (4c). The procedure for 1 was followed using 20 mg (0.037 mmol)
of 15d and 1 mL of 4 M HCl in dioxane to give 18 mg (95%) of 4c as
a 1:1 diastereomeric mixture: 1H NMR (300 MHz; CD3OD) δ 8.70−
8.58 (m, 1H), 8.45−8.30 (m, 1H), 7.88−7.45 (m, 8H), 7.32−7.20 (m,
2H), 4.52−4.40 (m, 0.5H), 4.38−4.28 (m, 0.5H), 3.88−3.56 (m, 1H),
3.48−3.35 (m, 1H), 3.15−3.05 (m, 0.5H), 3.05−2.95 (m, 0.5H),
2.80−2.60 (m, 2H), 2.25−2.10 (m, 1H), 2.10−1.90 (m, 1H), 1.87−
1.60 (m, 2H), 1.50−1.10 (m, 5H), 1.08−0.80 (m, 6H); HRMS (ESI)
calcd. for C29H35N3O [M + H]+: 442.2853. Found: 442.2867.
1
4i as a 1:1 diastereomeric mixture: H NMR (300 MHz; CD3OD) δ
8.35−8.22 (m, 1H), 8.05−7.92 (m, 2H), 7.90−7.75 (m, 1H), 7.72−
7.60 (m, 4H), 7.52−7.40 (m, 2H), 7.35−7.22 (m, 2H), 4.38−4.16 (m,
1H), 3.80−3.55 (m, 1H), 3.38−3.20 (m, 1H), 2.80−2.60 (m, 1H),
2.54 (s, 3H), 2.00−1.88 (m, 1H), 1.78−1.60 (m, 2H), 1.50−1.10 (m,
3H), 0.95−0.70 (m, 6H); HRMS (ESI) calcd. for C29H33N3O2 [M +
H]+: 456.2646. Found: 456.2658.
tert-Butyl (1R,2R)-2-(Pyridin-2-yl)cyclopropanecarboxylate
((1R,2R)-9). An oven-dried Schlenk tube, that was previously charged
with chiral porphyrin catalyst [Co(3,5-DitBu-ChenPhyrin)]11 (3.4 mg,
0.0025 mmol) and DMAP (15 mg, 0.13 mmol), was evacuated and
backfilled with nitrogen gas. Toluene (0.5 mL) and 2-vinylpyridine (8)
(26 mg, 0.25 mmol) were added, followed by the remaining solvent
(total 1.0 mL). The Schlenk tube was then placed in a −20 °C cooling
bath, and tert-butyl diazoacetate (41 μL, 0.3 mmol) was added
dropwise. After addition, the tube was purged with nitrogen for 2 min
and the mixture was stirred at −20 °C for 12 h, then at 0 °C for 12 h.
After warming to room temperature, the reaction was continued for
another 24 h. Flash column chromatography of the crude mixture on
silica gel using 10% EtOAc in hexanes afforded (1R,2R)-9 (35 mg,
64%) as a colorless oil. Assignment of the absolute configuration was
made based on the analogy to similar compounds with known absolute
configurations synthesized using the same chiral catalyst.11 The
enantiomeric excess (97% ee) was determined by HPLC (ChiralPak
AD-H column; 0.5% isopropanol/hexanes; flow rate 0.8 mL/min;
detection 254 nm; retention time 10.6 min).
(1R*,2R*)-2-(Pyridin-2-yl)cyclopropanecarboxylic Acid [(2S,3S)-2-
Amino-3-methylpentyl]-(4′-isobutylbiphenyl-4-yl)amide Dihydro-
chloride (4d). The procedure for 1 was followed using 20 mg
(0.035 mmol) of 15e and 1 mL of 4 M HCl in dioxane to give 17 mg
1
(90%) of 4d as a 1:1 diastereomeric mixture: H NMR (300 MHz;
CD3OD) δ 8.68−8.58 (m, 1H), 8.40−8.28 (m, 1H), 7.92−7.43 (m,
8H), 7.30−7.20 (m, 2H), 4.50−4.40 (m, 0.5H), 4.38−4.25 (m, 0.5H),
3.88−3.60 (m, 1H), 3.50−3.38 (m, 1H), 3.13−3.05 (m, 0.5H), 3.05−
2.90 (m, 0.5H), 2.51 (d, J = 6.0 Hz, 2H), 2.25−2.10 (m, 1H), 2.05−
1.60 (m, 4H), 1.50−1.20 (m, 2H), 1.10−0.76 (m, 12H); HRMS (ESI)
calcd. for C31H39N3O [M + H]+: 470.3166. Found: 470.3178.
(1R*,2R*)-2-(Pyridin-2-yl)cyclopropanecarboxylic Acid [(2S,3S)-2-
Amino-3-methylpentyl]-(4′-cyclohexylbiphenyl-4-yl)amide Dihydro-
chloride (4e). The procedure for 1 was followed using 20 mg (0.034
mmol) of 15f and 1 mL of 4 M HCl in dioxane to give 19 mg (98%) of
(1R,2R)-2-(Pyridin-2-yl)cyclopropanecarboxylic Acid Hydrochlor-
ide ((1R,2R)-10). To a solution of (1R,2R)-9 (110 mg, 0.50 mmol) in
CH2Cl2 (5 mL) was added 4 M HCl in dioxane (2 mL), and the
reaction was stirred at room temperature for 5 h. The solvent was
removed under reduced procedure. The residue was triturated with
CH2Cl2/Et2O to afford (1R,2R)-10 (95 mg, 95%) as a white solid: mp
1
4e as a 1:1 diastereomeric mixture: H NMR (300 MHz; CD3OD) δ
8.55−8.40 (m, 1H), 8.15−8.00 (m, 1H), 7.75−7.40 (m, 8H), 7.35−
7.20 (m, 2H), 4.48−4.20 (m, 1H), 3.88−3.68 (m, 1H), 3.42−3.35 (m,
1H), 2.98−2.88 (m, 1H), 2.68−2.48 (m, 1H), 2.20−2.00 (m, 1H),
1.98−1.70 (m, 7H), 1.66−1.10 (m, 8H), 1.05−0.78 (m, 6H); HRMS
(ESI) calcd. for C33H41N3O [M + H]+: 496.3322. Found: 496.3323.
(1R*,2R*)-2-(Pyridin-2-yl)cyclopropanecarboxylic Acid [(2S,3S)-2-
Amino-3-methylpentyl]-(4′-trifluoromethylbiphenyl-4-yl)amide Di-
hydrochloride (4f). The procedure for 1 was followed using 20 mg
(0.034 mmol) of 15g and 1 mL of 4 N HCl in dioxane to give 18 mg
155−157 °C; [α]23 −206.8° (c 0.5, CH3OH).
D
tert-Butyl [(2S,3S)-1-{4-Bromophenyl-[(1R,2R)-2-(pyridin-2-yl)-
cyclopropanecarbonyl]amino}-3-methylpentan-2-yl]carbamate
((1R,2R)-14). The procedure for 14 was followed using 108 mg (0.29
mmol) of 13 and 70 mg (0.35 mmol) of (1R,2R)-10 to give 97 mg
(65%) of (1R,2R)-14 as a white foam: [α]23 −21.0° (c 0.58,
D
1
1
(95%) of 4f as a 1:1 diastereomeric mixture: H NMR (300 MHz;
CH3OH); H NMR (300 MHz; CDCl3) δ 8.30 (d, J = 6.0 Hz, 1H),
CD3OD) δ 8.70−8.58 (m, 1H), 8.42−8.30 (m, 1H), 7.90−7.50 (m,
10H), 4.55−4.40 (m, 0.5H), 4.40−4.26 (m, 0.5H), 3.90−3.60 (m,
1H), 3.50−3.38 (m, 1H), 3.15−3.05 (m, 0.5H), 3.05−2.92 (m, 0.5H),
2.25−2.10 (m, 1H), 2.10−1.92 (m, 1H), 1.92−1.62 (m, 2H), 1.50−
1.15 (m, 2H), 1.08−0.80 (m, 6H); HRMS (ESI) calcd. for
C28H30F3N3O [M + H]+: 482.2414. Found: 482.2416.
7.56−7.40 (m, 3H), 7.22−7.06 (m, 3H), 7.06−6.98 (m, 1H), 4.96 (d, J
= 9.0 Hz, 1H), 4.36 (t, J = 12.0 Hz, 1H), 3.78−3.65 (m, 1H), 3.12 (dd,
J = 12.0, 3.0 Hz, 1H), 2.67 (ddd, J = 9.0, 6.0, 3.0 Hz, 1H), 1.93−1.86
(m, 1H), 1.61−1.53 (m, 1H), 1.52−1.41 (m, 3H), 1.45 (s, 9H), 1.15−
1.02 (m, 1H), 0.87 (d, J = 6.0 Hz, 3H), 0.85 (t, J = 7.5 Hz, 3H); 13C
NMR (75 MHz; CDCl3) δ 173.2, 159.3, 156.4, 149.4, 141.3, 136.0,
133.1, 130.1, 122.7, 121.9, 121.2, 79.0, 54.0, 50.3, 38.3, 28.6, 27.5, 25.3,
24.7, 18.3, 15.2, 11.9; MS (ESI) m/z 516.5 [M + H]+ (79Br), 518.4 [M
+ H]+ (81Br). The diastereomeric excess (>97% de) was determined
by HPLC (ChiralPak IA column; 5% EtOH/hexanes; flow rate 1 mL/
min; detection 220 nm; retention time 9.1 min).
(1R*,2R*)-2-(Pyridin-2-yl)cyclopropanecarboxylic Acid [(2S,3S)-2-
Amino-3-methylpentyl]-(4′-fluorobiphenyl-4-yl)amide Dihydro-
chloride (4g). The procedure for 1 was followed using 20 mg
(0.038 mmol) of 15h and 1 mL of 4 M HCl in dioxane to give 18 mg
1
(94%) of 4g as a 1:1 diastereomeric mixture: H NMR (300 MHz;
CD3OD) δ 8.70−8.58 (m, 1H), 8.45−8.35 (m, 1H), 7.90−7.50 (m,
8H), 7.25−7.10 (m, 2H), 4.52−4.40 (m, 0.5H), 4.40−4.25 (m, 0.5H),
3.90−3.60 (m, 1H), 3.52−3.40 (m, 1H), 3.16−3.06 (m, 0.5H), 3.05−
2.92 (m, 0.5H), 2.25−2.10 (m, 1H), 2.10−1.92 (m, 1H), 1.92−1.60
(m, 2H), 1.50−1.18 (m, 2H), 1.10−0.80 (m, 6H); HRMS (ESI) calcd.
for C27H30FN3O [M + H]+: 432.2446. Found: 432.2453.
tert-Butyl [(2S,3S)-1-{4-Bromophenyl-[(1S,2S)-2-(pyridin-2-yl)-
cyclopropanecarbonyl]amino}-3-methylpentan-2-yl]carbamate
((1S,2S)-14). The diastereomeric mixture 14 (350 mg) was separated
to (1R,2R)-14 (140 mg) and (1S,2S)-14 (137 mg) by preparative
HPLC using ChiralPak IA column: mobile phase, 5% EtOH/hexanes;
flow rate, 5 mL/min; detection 220 nm. The diastereomeric excess
H
dx.doi.org/10.1021/cn500082p | ACS Chem. Neurosci. XXXX, XXX, XXX−XXX

ACS Chemical Neuroscience
Research Article
(de) of both of separated compounds was determined to be >99% by
HPLC (ChiralPak IA column; 5% EtOH/hexanes; flow rate 1 mL/
min; detection 220 nm; retention time, (1R,2R)-14: 9.1 min, (1S,2S)-
J = 6.0 Hz, 3H); 13C NMR (75 MHz; CDCl3) δ 156.0, 147.3, 131.9,
114.1, 108.7, 79.7, 50.6, 46.3, 28.4, 19.0; MS (ESI) m/z 329.3 [M +
H]+ (79Br), 331.2 [M + H]+ (81Br).
tert-Butyl {(2S)-1-[(4′-Propylbiphenyl-4-yl)amino]-3-methylbu-
tan-2-yl}carbamate (18c). The procedure for 13 was followed
using 150 mg (0.71 mmol) of 4-(4′-propylphenyl)aniline (16) and
143 mg (0.71 mmol) of aldehyde 17c, prepared by oxidation of N-
14: 11.5 min). (1S,2S)-14: White foam; [α]23 +52.7° (c 0.55,
D
1
CH3OH); H NMR (300 MHz; CDCl3) δ 8.30 (d, J = 6.0 Hz, 1H),
7.52 (td, J = 9.0, 3.0 Hz, 1H), 7.40 (d, J = 6.0 Hz, 2H), 7.16 (d, J = 9.0
Hz, 1H), 7.12−6.99 (m, 3H), 4.96 (d, J = 9.0 Hz, 1H), 4.38 (dd, J =
15.0, 12.0 Hz, 1H), 3.72−3.58 (m, 1H), 3.15 (dd, J = 15.0, 3.0 Hz,
1H), 2.52 (ddd, J = 9.0, 6.0, 3.0 Hz, 1H), 1.97−1.90 (m, 1H), 1.70−
1.63 (m, 1H), 1.54−1.38 (m, 3H), 1.40 (s, 9H), 1.14−1.02 (m, 1H),
0.87 (d, J = 6.0 Hz, 3H), 0.84 (t, J = 7.5 Hz, 3H); 13C NMR (75 MHz;
CDCl3) δ 173.1, 159.2, 156.2, 149.5, 141.1, 135.9, 132.9, 130.1, 122.5,
121.8, 121.2, 78.9, 53.8, 50.0, 38.2, 28.6, 28.1, 25.3, 24.7, 17.7, 15.2,
11.9; MS (ESI) m/z 516.5 [M + H]+ (79Br), 518.4 [M + H]+ (81Br).
(1R,2R)-2-(Pyridin-2-yl)cyclopropanecarboxylic Acid [(2S,3S)-2-
Amino-3-methylpentyl]-(4′-propylbiphenyl-4-yl)amide Dihydro-
chloride (2). The procedure for 15a was followed using 120 mg
(0.23 mmol) of (1R,2R)-14, followed by deprotection of the Boc
protecting group with 4 M HCl in dioxane, to give 97 mg (80% over
two steps) of 2 as a white solid: mp 125 °C (fusion); [α]23D +6.3° (c 1,
CH3OH); 1H NMR (300 MHz; CD3OD) δ 8.58 (d, J = 6.0 Hz, 1H),
8.28 (t, J = 9.0 Hz, 1H), 7.78−7.52 (m, 6H), 7.51 (d, J = 9.0 Hz, 2H),
7.27 (d, J = 9.0 Hz, 2H), 4.29 (dd, J = 15.0, 9.0 Hz, 1H), 3.83 (d, J =
12.0 Hz, 1H), 3.48−3.38 (m, 1H), 3.01−2.90 (m, 1H), 2.62 (t, J = 7.5
Hz, 2H), 2.22−2.12 (m, 1H), 2.02−1.92 (m, 1H), 1.90−1.75 (M, 1H),
1.75−1.60 (m, 3H), 1.50−1.35 (m, 1H), 1.35−1.15 (m, 1H), 1.05−
0.90 (m, 6H), 0.86 (t, J = 6.0 Hz, 3H); 13C NMR (75 MHz; CD3OD)
δ 173.4, 157.6, 146.6, 143.9, 143.3, 142.9, 141.6, 138.2, 130.2, 129.8,
129.5, 127.9, 125.5, 125.1, 56.6, 50.9, 38.7, 37.2, 27.4, 26.5, 25.7, 25.2,
18.1, 14.2, 14.2, 11.7; HRMS (ESI) calcd. for C30H37N3O [M + H]+:
456.3009. Found: 456.3023. The diastereomeric excess (>99% de) was
determined by HPLC (XTerra MS C-18 column; gradient 40−60% of
(0.1%TFA/MeCN)/(0.1%TFA/water); flow rate 1 mL/min; detec-
tion 254 nm; retention time 5.66 min).
Boc-L-valinol, to give 185 mg (66%) of 18c as a white solid: mp 83−85
1
°C; [α]23 +22.2° (c 0.54, CH3OH); H NMR (300 MHz; CDCl3) δ
D
7.45 (d, J = 9.0 Hz, 2H), 7.42 (d, J = 9.0 Hz, 2H), 7.20 (d, J = 9.0 Hz,
2H), 6.65 (d, J = 9.0 Hz, 2H), 4.51 (d, J = 6.0 Hz, 1H), 4.12 (br s,
1H), 3.80−3.65 (m, 1H), 3.35−3.20 (m, 1H), 3.12−3.00 (m, 1H),
2.60 (t, J = 7.5 Hz, 2H), 1.95−1.80 (m, 1H), 1.75−1.58 (m, 2H), 1.45
(s, 9H), 1.05−0.90 (m, 9H); 13C NMR (75 MHz; CDCl3) δ 156.8,
147.8, 140.5, 138.8, 130.3, 128.9, 127.8, 126.2, 113.0, 79.5, 55.7, 47.1,
37.8, 30.6, 28.5, 24.7, 19.6, 18.2, 14.0; MS (ESI) m/z 397.5 [M + H]+.
tert-Butyl {(2S)-1-[(4′-Propylbiphenyl-4-yl)amino]-4-methylpen-
tan-2-yl}carbamate (18d). The procedure for 13 was followed
using 90 mg (0.43 mmol) of 16 and 93 mg (0.43 mmol) of aldehyde
17d, prepared by oxidation of N-Boc-L-leucinol, to give 120 mg (68%)
of 18d as a white solid: mp 98−100 °C; [α]23 +2.4° (c 0.54,
D
1
CH3OH); H NMR (300 MHz; CDCl3) δ 7.45 (d, J = 9.0 Hz, 2H),
7.42 (d, J = 9.0 Hz, 2H), 7.22 (d, J = 9.0 Hz, 2H), 6.66 (d, J = 9.0 Hz,
2H), 4.41 (br s, 1H), 4.21 (br s, 1H), 4.00−3.82 (m, 1H), 3.32−3.20
(m, 1H), 3.12−3.00 (m, 1H), 2.62 (t, J = 7.5 Hz, 2H), 1.80−1.60 (m,
3H), 1.45 (s, 9H), 1.43−1.35 (m, 2H), 1.05−0.90 (m, 9H); 13C NMR
(75 MHz; CDCl3) δ 156.3, 147.7, 140.5, 138.7, 130.2, 128.7, 127.8,
126.1, 112.9, 79.5, 49.9, 49.0, 42.5, 37.7, 28.4, 25.0, 24.6, 23.1, 22.1,
13.9; MS (ESI) m/z 411.5 [M + H]+.
tert-Butyl {(2S)-1-[(4-Bromophenyl)amino]-3-phenylpropan-2-
yl}carbamate (18e). The procedure for 13 was followed using 172
mg (1.00 mmol) of 11 and 250 mg (1.00 mmol) of N-Boc-L-
phenylalaninal (17e) to give 350 mg (86%) of 18e as a white solid: mp
1
124−126 °C; [α]23 +12.2° (c 0.53, CH3OH); H NMR (300 MHz;
D
(1S,2S)-2-(Pyridin-2-yl)cyclopropanecarboxylic Acid [(2S,3S)-2-
Amino-3-methylpentyl]-(4′-propylbiphenyl-4-yl)amide Dihydro-
chloride (3). The procedure for 15a was followed using 120 mg
(0.23 mmol) of (1S,2S)-14, followed by deprotection of the Boc
protecting group with 4 M HCl in dioxane, to give 98 mg (81% over
two steps) of 3 as a white solid: mp 122 °C (fusion); [α]23D −91.3° (c
1, CH3OH); 1H NMR (300 MHz; CD3OD) δ 8.62 (br d, J = 3.0 Hz,
1H), 8.31 (br t, J = 7.5 Hz, 1H), 7.80−7.58 (m, 6H), 7.49 (d, J = 9.0
Hz, 2H), 7.26 (d, J = 9.0 Hz, 2H), 4.46 (dd, J = 15.0, 9.0 Hz, 1H), 3.68
(d, J = 15.0 Hz, 1H), 3.46−3.38 (m, 1H), 3.12−3.02 (m, 1H), 2.61 (t,
J = 7.5 Hz, 2H), 2.25−2.05 (m, 1H), 1.98−1.86 (m, 1H), 1.86−1.60
(m, 4H), 1.45−1.15 (m, 2H), 1.10−0.90 (m, 6H), 0.82 (t, J = 6.0 Hz,
3H); 13C NMR (75 MHz; CD3OD) δ 173.3, 157.5, 146.7, 143.9,
143.3, 142.9, 141.4, 138.2, 130.2, 130.0, 129.4, 127.9, 125.6, 125.3,
56.5, 50.6, 38.7, 37.4, 27.0, 26.7, 25.7, 25.6, 17.2, 14.1, 11.8; HRMS
(ESI) calcd. for C30H37N3O [M + H]+: 456.3009. Found: 456.3018.
The diastereomeric excess (>99% de) was determined by HPLC
(XTerra MS C-18 column; gradient 40−60% of (0.1%TFA/MeCN)/
(0.1%TFA/water); flow rate 1 mL/min; detection 254 nm; retention
time 6.35 min).
CDCl3) δ 7.36−7.15 (m, 7H), 6.43 (d, J = 9.0 Hz, 2H), 4.51 (br s,
1H), 4.15−3.98 (m, 2H), 3.26−3.15 (m, 1H), 3.10−2.92 (m, 1H),
2.96−1.80 (m, 2H), 1.41 (s, 9H); 13C NMR (75 MHz; CDCl3) δ
156.0, 147.1, 137.3, 131.9, 129.2, 128.7, 126.8, 114.3, 109.0, 79.8, 51.4,
47.9, 39.2, 28.3; MS (ESI) m/z 405.3 [M + H]+ (79Br), 407.3 [M +
H]+ (81Br).
tert-Butyl (2-{4-Bromophenyl-[(1R*,2R*)-2-(pyridin-2-yl)-
cyclopropanecarbonyl]amino}ethyl)carbamate (19a). The proce-
dure for 14 was followed using 180 mg (0.57 mmol) of 18a and 136
mg (0.68 mmol) of racemic 10 to give 140 mg (53%) of 19a as a
1
yellow oil: H NMR (300 MHz; CDCl3) δ 8.31 (d, J = 6.0 Hz, 1H),
7.60−7.50 (m, 1H), 7.43 (d, J = 9.0 Hz, 2H), 7.21−7.00 (m, 4H), 5.05
(br s, 1H), 3.92−3.80 (m, 2H), 3.40−3.25 (m, 2H), 2.68−2.58 (m,
1H), 2.00−1.90 (m, 1H), 1.70−1.58 (m, 1H), 1.41 (s, 9H), 1.20−1.05
(m, 1H); MS (ESI) m/z 460.3 [M + H]+ (79Br), 462.1 [M + H]+
(81Br). This product contained impurity as judged by 1H NMR
analysis, which was used in the next step without further purification.
tert-Butyl [(2S)-1-{4-Bromophenyl-[(1R*,2R*)-2-(pyridin-2-yl)-
cyclopropanecarbonyl]amino}propan-2-yl]carbamate (19b). The
procedure for 14 was followed using 99 mg (0.30 mmol) of 18b
and 72 mg (0.36 mmol) of racemic 10 to give 85 mg (60%) of 19b as
a 1:1 diastereomeric mixture: 1H NMR (300 MHz; CDCl3) δ 8.30 (d,
J = 6.0 Hz, 1H), 7.58−7.36 (m, 3H), 7.20−6.95 (m, 4H), 4.98 (d, J =
6.0 Hz, 1H), 4.22−4.05 (m, 1H), 3.92−3.70 (m, 1H), 3.32−3.18 (m,
2H), 2.68−2.60 (m, 0.5H), 2.60−2.46 (m, 0.5H), 1.95−1.80 (m, 1H),
1.68−1.52 (m, 1H), 1.43 and 1.41 (2s, 9H), 1.10 (d, J = 6.0 Hz, 3H);
MS (ESI) m/z 474.4 [M + H]+ (79Br), 476.5 [M + H]+ (81Br).
tert-Butyl (2S)-1-{(4′-Propylbiphenyl-4-yl)-[(1R*,2R*)-2-(pyridin-
2-yl)cyclopropanecarbonyl]amino}-3-methylbutan-2-yl}carbamate
(19c). The procedure for 14 was followed using 120 mg (0.34 mmol)
of 18c and 81 mg (0.40 mmol) of racemic 10 to give 110 mg (60%) of
tert-Butyl {2-[(4-Bromophenyl)amino]ethyl}carbamate (18a).
The procedure for 13 was followed using 1.03 g (5.96 mmol) of 11
and 0.95 g (5.96 mmol) of N-Boc-2-aminoacetaldehyde (17a) to give
1
1.38 g (50%) of 18a as a yellow oily residue: H NMR (300 MHz;
CDCl3) δ 7.23 (d, J = 9.0 Hz, 2H), 6.48 (d, J = 9.0 Hz, 2H), 4.80 (br s,
1H), 4.10 (br s, 1H), 3.41−3.30 (m, 2H), 3.30−3.26 (m, 2H), 1.45 (s,
9H); 13C NMR (75 MHz; CDCl3) δ 156.5, 147.1, 131.9, 114.2, 108.8,
79.6, 44.4, 40.0, 28.4; MS (ESI) m/z 315.1 [M + H]+ (79Br), 317.2 [M
+ H]+ (81Br).
tert-Butyl {(2S)-1-[(4-Bromophenyl)amino]propan-2-yl}-
carbamate (18b). The procedure for 13 was followed using 247 mg
(1.44 mmol) of 11 and 250 mg (1.44 mmol) of N-Boc-L-alaninal
1
19c as a 1:1 diastereomeric mixture: H NMR (300 MHz; CDCl3) δ
(17b) to give 410 mg (86%) of 18b as a white solid: mp 115−117 °C;
1
[α]23 +3.1° (c 0.52, CH3OH); H NMR (300 MHz; CDCl3) δ 7.23
8.26−8.18 (m, 1H), 7.55−7.34 (m, 5H), 7.30−7.21 (m, 5H), 6.98−
6.90 (m, 1H), 5.08−4.92 (m, 1H), 4.45−4.32 (m, 1H), 3.80−3.60 (m,
1H), 3.25−3.12 (m, 1H), 2.74−2.48 (m, 3H), 2.08−1.92 (m, 1H),
D
(d, J = 9.0 Hz, 2H), 6.48 (d, J = 9.0 Hz, 2H), 4.48 (br s, 1H), 4.12 (br
s, 1H), 4.00−3.86 (m, 1H), 3.18−2.98 (m, 2H), 1.45 (s, 9H), 1.21 (d,
I
dx.doi.org/10.1021/cn500082p | ACS Chem. Neurosci. XXXX, XXX, XXX−XXX

ACS Chemical Neuroscience
Research Article
1.78−1.52 (m, 5H), 1.47 and 1.43 (2s, 9H), 1.00−0.80 (m, 9H); MS
(ESI) m/z 542.6 [M + H]+.
and 1 mL of 4 M HCl in dioxane to give 37 mg (98%) of 5b as a 1:1
diastereomeric mixture: H NMR (300 MHz; CD3OD) δ 8.70−8.58
1
tert-Butyl (2S)-1-{(4′-Propylbiphenyl-4-yl)-[(1R*,2R*)-2-(pyridin-
2-yl)cyclopropanecarbonyl]amino}-4-methylpentan-2-yl}-
carbamate (19d). The procedure for 14 was followed using 90 mg
(0.22 mmol) of 18d and 53 mg (0.26 mmol) of racemic 10 to give 65
(m, 1H), 8.40−8.28 (m, 1H), 7.85−7.40 (m, 8H), 7.30−7.20 (m, 2H),
4.42−4.26 (m, 0.5H), 4.25−4.10 (m, 0.5H), 3.95−3.82 (m, 0.5H),
3.78−3.48 (m, 1.5H), 3.10−2.90 (m, 1H), 2.62 (t, J = 7.5 Hz, 2H),
2.22−2.06 (m, 1H), 2.05−1.85 (m, 1H), 1.78−1.68 (m, 3H), 1.42−
1.20 (m, 3H), 0.95 (t, J = 6.0 Hz, 3H); HRMS (ESI) calcd. for
C27H31N3O [M + H]+: 414.2540. Found: 414.2547.
1
mg (53%) of 19d as a 1:1 diastereomeric mixture: H NMR (300
MHz; CDCl3) δ 8.28−8.20 (m, 1H), 7.55−7.35 (m, 5H), 7.32−7.12
(m, 5H), 7.00−6.90 (m, 1H), 4.90−4.80 (m, 1H), 4.28−4.12 (m, 1H),
4.00−3.80 (m, 1H), 3.38−3.20 (m, 1H), 2.75−2.50 (m, 3H), 2.10−
1.90 (m, 1H), 1.76−1.52 (m, 5H), 1.45 and 1.41 (2s, 9H), 1.40−1.12
(m, 2H), 1.02−0.80 (m, 9H); MS (ESI) m/z 556.8 [M + H]+.
tert-Butyl [(2S)-1-{4-Bromophenyl-[(1R*,2R*)-2-(pyridin-2-yl)-
cyclopropanecarbonyl]amino}-3-phenylpropan-2-yl]carbamate
(19e). The procedure for 14 was followed using 99 mg (0.30 mmol) of
18e and 72 mg (0.36 mmol) of racemic 10 to give 85 mg (60%) of
(1R*,2R*)-2-(Pyridin-2-yl)cyclopropanecarboxylic Acid [(2S)-2-
Amino-3-methylbutyl]-(4′-propylbiphenyl-4-yl)amide Dihydrochlor-
ide (5c). The procedure for 1 was followed using 60 mg (0.11 mmol)
of 19c and 1 mL of 4 M HCl in dioxane to give 54 mg (95%) of 5c as
a 1:1 diastereomeric mixture: 1H NMR (300 MHz; CD3OD) δ 8.55−
8.38 (m, 1H), 8.22−8.10 (m, 1H), 7.70−7.30 (m, 8H), 7.25−7.10 (m,
2H), 4.38−4.25 (m, 0.5H), 4.24−4.10 (m, 0.5H), 3.88−3.40 (m, 2H),
3.30−3.10 (m, 1H), 2.98−2.80 (m, 1H), 2.52 (t, J = 7.5 Hz, 2H),
2.16−1.78 (m, 3H), 1.68−1.46 (m, 2H), 1.00−0.75 (m, 9H); HRMS
(ESI) calcd. for C29H35N3O [M + H]+: 442.2853. Found: 442.2856.
(1R*,2R*)-2-(Pyridin-2-yl)cyclopropanecarboxylic Acid [(2S)-2-
Amino-4-methylpentyl]-(4′-propylbiphenyl-4-yl)amide Dihydro-
chloride (5d). The procedure for 1 was followed using 50 mg (0.09
mmol) of 19d and 1 mL of 4 M HCl in dioxane to give 46 mg (97%)
of 5d as a 1:1 diastereomeric mixture: 1H NMR (300 MHz; CD3OD)
δ 8.60−8.50 (m, 1H), 8.30−8.18 (m, 1H), 7.78−7.40 (m, 8H), 7.27
(d, J = 9.0 Hz, 2H), 4.36−4.20 (m, 0.5H), 4.20−4.18 (m, 0.5H), 4.05−
3.90 (m, 0.5H), 3.88−3.60 (m, 1.5H), 3.52−3.40 (m, 1H), 3.10−2.90
(m, 1H), 2.62 (t, J = 7.5 Hz, 2H), 2.22−2.08 (m, 1H), 2.00−1.88 (m,
1H), 1.76−1.42 (m, 5H), 1.02−0.75 (m, 9H); HRMS (ESI) calcd. for
C30H37N3O [M + H]+: 456.3009. Found: 456.3017.
(1R*,2R*)-2-(Pyridin-2-yl)cyclopropanecarboxylic Acid [(2S)-2-
Amino-3-phenylpropyl]-(4′-propylbiphenyl-4-yl)amide Dihydro-
chloride (5e). The procedure for 1 was followed using 70 mg (0.12
mmol) of 20e and 1 mL of 4 M HCl in dioxane to give 65 mg (96%)
of 5e as a 1:1 diastereomeric mixture: 1H NMR (300 MHz; CD3OD)
δ 8.65−8.58 (m, 1H), 8.40−8.26 (m, 1H), 7.82−7.70 (m, 1H), 7.70−
7.36 (m, 7H), 7.35−7.05 (m, 7H), 4.45−4.30 (m, 0.5H), 4.25−4.10
(m, 0.5H), 4.00−3.86 (m, 0.5H), 3.85−3.55 (m, 1.5H), 3.16−2.88 (m,
3H), 2.69 (t, J = 7.5 Hz, 2H), 2.22−2.05 (m, 1H), 2.05−1.88 (m, 1H),
1.76−1.58 (m, 3H), 0.95 (t, J = 7.5 Hz, 3H); HRMS (ESI) calcd. for
C33H35N3O [M + H]+: 490.2853. Found: 490.2859.
tert-Butyl [(2S,3S)-1-{4-Bromophenyl-[(1R,2R)-2-phenyl-1-
cyclopropanecarbonyl]amino}-3-methylpentan-2-yl]carbmate
(21a). A solution of (1R,2R)-2-phenyl-1-cyclopropanecarboxylic acid12
(97 mg, 0.6 mmol) in thionyl chloride (3 mL) was refluxed overnight.
After cooling to room temperature, the mixture was concentrated
under reduced pressure. The resulting residue was dissolved in CH2Cl2
(5 mL) and treated with 13 (150 mg, 0.4 mmol) and Et3N (0.17 mL,
1.2 mmol). The reaction mixture was stirred at room temperature
overnight. Saturated NaHCO3 (5 mL) was added and the layers were
separated. The aqueous layer was extracted with CH2Cl2 (3 × 10 mL).
The combined organic layers were washed with brine (3 × 10 mL),
dried (Na2SO4), and concentrated under reduced pressure. Flash
column chromatography of the crude product on silica gel using 0−
25% EtOAc in hexanes afforded 21a (155 mg, 75%) as a white foam:
[α]23D +35.2° (c 0.52, CH3OH); 1H NMR (300 MHz; CDCl3) δ 7.49
(d, J = 9.0 Hz, 2H), 7.25−7.10 (m, 5H), 6.94 (d, J = 9.0 Hz, 2H), 4.96
(d, J = 12.0 Hz, 1H), 4.37 (dd, J = 12.0, 10.5 Hz, 1H), 3.80−3.66 (m,
1H), 3.13 (dd, J = 12.0, 3.0 Hz, 1H), 2.66−2.55 (m, 1H), 1.61−1.48
(m, 4H), 1.45 (s, 9H), 1.16−1.10 (m, 2H), 0.91−0.82 (m, 6H); 13C
NMR (75 MHz; CDCl3) δ 173.3, 156.4, 141.4, 140.4, 133.1, 130.2,
128.5, 126.4, 122.0, 79.0, 54.1, 50.3, 38.3, 28.6, 26.4, 25.4, 24.1, 17.8,
15.3, 11.9; MS (ESI) m/z 515.4 [M + H]+ (79Br), 517.4 [M + H]+
(81Br).
1
19e as a 1:1 diastereomeric mixture: H NMR (300 MHz; CDCl3) δ
8.29 (d, J = 6.0 Hz, 1H), 7.55−7.30 (m, 3H), 7.30−6.90 (m, 9H),
5.05−4.92 (m, 1H), 4.28−3.90 (m, 2H), 3.30−3.20 (m, 1H), 2.88−
2.48 (m, 3H), 1.95−1.82 (m, 1H), 1.70−1.50 (m, 1H), 1.39 and 1.37
(2s, 9H), 1.32−1.20 (m, 1H); MS (ESI) m/z 550.4 [M + H]+ (79Br),
552.5 [M + H]+ (81Br).
tert-Butyl (2-{(4′-Propylbiphenyl-4-yl)-[(1R*,2R*)-2-(pyridin-2-yl)-
cyclopropanecarbonyl]amino}ethyl)carbamate (20a). The proce-
dure for 15a was followed using 140 mg (0.30 mmol) of 19a and 83
mg (0.47 mmol) of 4-propylphenylboronic acid to give 80 mg (53%)
1
of 20a: H NMR (300 MHz; CDCl3) δ 8.22 (d, J = 6.0 Hz, 1H),
7.55−7.40 (m, 5H), 7.25−7.12 (m, 5H), 7.00−6.90 (m, 1H), 5.17 (br
s, 1H), 3.90 (t, J = 6.0 Hz, 2H), 3.42−3.25 (m, 3H), 2.62 (t, J = 7.5
Hz, 2H), 2.10−1.98 (m, 1H), 1.75−1.60 (m, 2H), 1.55−1.35 (m, 2H),
1.42 (s, 9H), 0.97 (t, J = 6.0 Hz, 3H); 13C NMR (75 MHz; CDCl3) δ
172.9, 159.4, 156.1, 149.3, 142.3, 141.0, 137.4, 135.8, 129.7, 129.0,
128.2, 128.1, 126.9, 122.4, 121.0, 79.1, 49.2, 39.7, 37.7, 28.4, 27.7, 24.9,
24.5, 17.7, 13.9; MS (ESI) m/z 500.8 [M + H]+.
tert-Butyl [(2S)-1-{(4′-Propylbiphenyl-4-yl)-[(1R*,2R*)-2-(pyridin-
2-yl)cyclopropanecarbonyl]amino}propan-2-yl]carbamate (20b).
The procedure for 15a was followed using 50 mg (0.11 mmol) of
19b and 29 mg (0.16 mmol) of 4-propylphenylboronic acid to give 45
1
mg (80%) of 20b as a 1:1 diastereomeric mixture: H NMR (300
MHz; CDCl3) δ 8.28−8.18 (m, 1H), 7.56−7.38 (m, 5H), 7.28−7.10
(m, 5H), 7.00−6.90 (m, 1H), 5.20−5.06 (m, 1H), 4.32−4.15 (m, 1H),
3.96−3.78 (m, 1H), 3.38−3.22 (m, 1H), 2.70−2.48 (m, 3H), 2.06−
1.90 (m, 2H), 1.78−1.58 (m, 3H), 1.45 and 1.43 (2s, 9H), 1.12 (d, J =
6.0 Hz, 3H), 0.97 (t, J = 7.5 Hz, 3H); MS (ESI) m/z 514.6 [M + H]+.
tert-Butyl [(2S)-1-{(4′-Propylbiphenyl-4-yl)-[(1R*,2R*)-2-(pyridin-
2-yl)cyclopropanecarbonyl]amino}-3-phenylpropan-2-yl]-
carbamate (20e). The procedure for 15a was followed using 90 mg
(0.16 mmol) of 19e and 44 mg (0.24 mmol) of 4-propylphenylboronic
1
acid to give 75 mg (80%) of 20e as a 1:1 diastereomeric mixture: H
NMR (300 MHz; CDCl3) δ 8.26−8.15 (m, 1H), 7.55−7.38 (m, 6H),
7.28−7.05 (m, 9H), 7.00−6.90 (m, 1H), 5.16−5.05 (m, 1H), 4.35−
4.18 (m, 1H), 4.15−3.95 (m, 1H), 3.34−3.22 (m, 1H), 2.88−2.45 (m,
5H), 2.05−1.90 (m, 1H), 1.75−1.50 (m, 3H), 1.41 and 1.40 (2s, 9H),
1.30−1.20 (m, 1H), 0.97 (t, J = 7.5 Hz, 3H); MS (ESI) m/z 590.8 [M
+ H]+.
(1R*,2R*)-2-(Pyridin-2-yl)cyclopropanecarboxylic Acid [2-Amino-
ethyl-(4′-propylbiphenyl-4-yl)amide Dihydrochloride (5a). The
procedure for 1 was followed using 60 mg (0.12 mmol) of 20a and
1 mL of 4 M HCl in dioxane to give 52 mg (92%) of 5a as a light
1
yellow foam: H NMR (300 MHz; CD3OD) δ 8.56 (br s, 1H), 8.23
(br t, 1H), 7.50−7.63 (m, 3H), 7.62−7.43 (m, 5H), 7.27 (d, J = 9.0
Hz, 2H), 4.25−3.98 (m, 2H), 3.22−3.10 (m, 2H), 3.00−2.78 (m, 1H),
2.63 (t, J = 7.5 Hz, 2H), 2.18−2.08 (m, 1H), 1.94−182 (m, 1H),
1.72−1.60 (m, 3H), 0.96 (t, J = 7.5 Hz, 3H); 13C NMR (75 MHz;
CD3OD) δ 173.1, 157.9, 146.2, 144.1, 143.9, 143.0, 141.4, 138.2,
130.2, 130.0, 129.6, 128.0, 125.5, 125.3, 39.9, 38.7, 27.1, 25.8, 25.7,
18.0, 14.1; HRMS (ESI) calcd. for C26H29N3O [M + H]+: 400.2383.
Found: 400.2388.
tert-Butyl [(2S,3S)-1-{4-Bromophenyl-[(pyridin-2-yl)-
methylcarbonyl]amino}-3-methylpentan-2-yl]carbamate (21b). To
a solution of 13 (200 mg, 0.54 mmol) in CH3CN (10 mL) at room
temperature were added 2-pyridylacetic acid hydrochloride (113 mg,
0.65 mmol), Et3N (0.23 mL, 1.6 mmol), and HBTU (246 mg, 0.65
mmol). The reaction mixture was stirred at room temperature
overnight. The solution was diluted with EtOAc (50 mL) and washed
with saturated NaHCO3 (10 mL) and brine (10 mL). The organic
(1R*,2R*)-2-(Pyridin-2-yl)cyclopropanecarboxylic Acid [(2S)-2-
Aminopropyl-(4′-propylbiphenyl-4-yl)amide Dihydrochloride (5b).
The procedure for 1 was followed using 40 mg (0.078 mmol) of 20b
J
dx.doi.org/10.1021/cn500082p | ACS Chem. Neurosci. XXXX, XXX, XXX−XXX

ACS Chemical Neuroscience
Research Article
phase was dried (Na2SO4) and concentrated under reduced pressure.
Flash column chromatography of the crude product on silica gel using
0−25% EtOAc in hexanes afforded 21b (170 mg, 64%) as a brown
GPR88 cDNA was purchased from Missouri S&T cDNA Resource
Center. The pGloSensor-22F plasmid was purchased from Promega.
Transient Transfection and cAMP Assay. HEK293T cells were
transfected with human GPR88 cDNA and pGloSensor-22F overnight
and plated in the poly-L-lysine coated 384-well white clear bottom cell
culture plates using DMEM supplemented with 1% dialyzed fetal
bovine serum at a density of 15,000 cells in 40 μL medium per well.
The cell plates were incubated for 6−20 h before being used for assays.
To measure receptor mediated Gαi-activation, culture medium was
removed and assay buffer (20 μL per well of 20 mM HEPES, 1×
HBSS, pH 7.4) was added, followed by addition of 10 μL of test
compound solution at serially diluted concentrations for 15 min at
room temperature. After addition of 15 μL of Luciferin (4 mM final)
and isoproterenol (200 nM final) and incubation for another 15 min,
luminescence was read on the TriLux microbeta counter (PerkinElm-
er). To measure receptor mediated Gαs-activation, cells were first
incubated with test compound for 15 min followed by 15 μL of 4 mM
Luciferin for another 15 min, and then luminescence counted as above.
GloSensor cAMP Assay Using Stable GPR88-22F HEK293 Cells. A
GPR88-22F stable cell line was created by overexpressing the human
GPR88 receptor and the pGloSensor-22F biosensor in HEK293 cells.
The day before the assay, GPR88-22F cells were plated into 96-well
white-walled assay plates at a density of 40 000 cells per well in culture
medium (DMEM-HG supplemented with 10% FBS, 15 mM HEPES,
and 100 units of penicillin/streptomycin). The plated cells were
incubated overnight at 37 °C, 5% CO2. The next day, the culture
medium was gently removed and 100 μL of equilibration medium was
gently added per the manufacturer’s instructions (88% CO2-
independent medium, 10% FBS, 2% GloSensor cAMP reagent). The
cells were incubated in the equilibration medium for 2 h at room
temperature in the dark. Test compound dilutions were prepared at
11× concentration in 1× PBS and 10 μL was added to each
appropriate well. Following 10 min at room temperature in the dark,
10 μL of 100 nM (final) isoproterenol (prepared at 12× concentration
in 1× PBS) was added to each appropriate well. Following 30 min at
room temperature in the dark, luminescence was read on the
FlexStation III (1000 ms integration time, Molecular Devices).
Data Analysis. Relative luminescence units (RLU) were recorded
and plotted against compound concentration. Data were fit to a three-
parameter logistic function to generate EC50 values using GraphPad
Prism software (San Diego, CA).
1
residue: H NMR (300 MHz; CDCl3) δ 8.40 (d, J = 3.0 Hz, 1H),
7.56−7.48 (m, 1H), 7.47 (d, J = 9.0 Hz, 2H), 7.13−6.98 (m, 4H), 4.89
(d, J = 9.0 Hz, 1H), 4.30 (t, J = 12.0 Hz, 1H), 3.70−3.55 (m, 1H), 3.54
(s, 2H), 3.06 (dd, J = 15.0, 3.0 Hz, 1H), 1.50−1.42 (m, 2H), 1.41 (s,
9H), 1.10−0.92 (m, 1H), 0.83−0.70 (m, 6H); 13C NMR (75 MHz;
CDCl3) δ 169.9, 155.1, 154.5, 148.3, 140.1, 135.3, 132.0, 129.2, 122.8,
121.3, 120.7, 77.9, 52.5, 49.0, 42.9, 37.0, 27.4, 24.2, 14.0, 10.7; MS
(ESI) m/z 490.8 [M + H]+ (79Br), 492.6 [M + H]+ (81Br).
tert-Butyl [(2S,3S)-1-{(4′-Propylbiphenyl-4-yl)-[(1R,2R)-2-phenyl-
1-cyclopropanecarbonyl]amino}-3-methylpentan-2-yl]carbamate
(22a). The procedure for 15a was followed using 100 mg (0.19 mmol)
of 21a and 54 mg (0.32 mmol) of 4-propylphenylboronic acid to give
80 mg (76%) of 22a as a white foam: [α]23D +71.4° (c 0.52, CH3OH);
1H NMR (300 MHz; CDCl3) δ 7.56 (d, J = 9.0 Hz, 2H), 7.48 (d, J =
9.0 Hz, 2H), 7.36−7.22 (m, 4H), 7.21−7.01 (m, 3H), 6.94 (d, J = 9.0
Hz, 2H), 5.08 (d, J = 12.0 Hz, 1H), 4.43 (t, J = 12.0 Hz, 1H), 3.86−
3.72 (m, 1H), 3.19 (dd, J = 13.5, 4.5 Hz, 1H), 2.70−2.56 (m, 3H),
1.76−1.55 (m, 6H), 1.47 (s, 9H), 1.18−1.04 (m, 2H), 1.00 (t, J = 7.5
Hz, 3H), 0.93−0.82 (m, 6H); 13C NMR (75 MHz; CDCl3) δ 173.5,
156.4, 142.3, 141.0, 140.7, 140.5, 137.3, 129.0, 128.6, 128.3, 128.1,
126.9, 126.4, 126.2, 78.7, 54.1, 50.0, 38.2, 37.7, 28.5, 26.1, 25.3, 24.5,
23.9, 17.6, 15.1, 13.8, 11.8; MS (ESI) m/z 555.8 [M + H]+.
tert-Butyl [(2S,3S)-1-{(4′-Propylbiphenyl-4-yl)[(pyridin-2-yl)-
methylcarbonyl]amino}-3-methylpentan-2-yl]carbamate (22b).
The procedure for 15a was followed using 170 mg (0.35 mmol) of
21b and 96 mg (0.54 mmol) of 4-propylphenylboronic acid to give
1
101 mg (55%) of 22b as an oil: H NMR (300 MHz; CDCl3) δ 8.47
(d, J = 3.0 Hz, 1H), 765−7.56 (m, 3H), 7.50 (d, J = 9.0 Hz, 2H),
7.42−7.08 (m, 6H), 5.08 (d, J = 9.0 Hz, 1H), 4.44 (t, J = 12.0 Hz, 1H),
3.86−3.74 (m, 1H), 3.69 (s, 2H), 3.08 (dd, J = 15.0, 3.0 Hz, 1H), 2.63
(t, J = 7.5 Hz, 2H), 1.76−1.65 (m, 2H), 1.64−1.47 (m, 2H), 1.45 (s,
9H), 1.16−1.02 (m, 1H), 0.97 (t, J = 7.5 Hz, 3H), 0.92−0.78 (m, 6H);
13C NMR (75 MHz; CDCl3) δ 171.3, 156.2, 155.9, 149.2, 142.4, 141.2,
140.9, 137.3, 130.2, 129.0, 128.7, 128.3, 126.9, 123.9, 121.6, 78.8, 53.7,
49.9, 43.9, 38.0, 37.7, 28.5, 25.3, 24.5, 15.0, 13.8, 11.8; MS (ESI) m/z
530.9 [M + H]+.
(1R,2R)-2-Phenyl-1-cyclopropanecarboxylic Acid [(2S,3S)-2-
Amino-3-methylpentyl]-(4′-propylbiphenyl-4-yl)amide Hydrochlor-
ide (6a). The procedure for 1 was followed using 60 mg (0.11 mmol)
of 22a and 1 mL of 4 M HCl in dioxane to give 52 mg (96%) of 6a as
a white solid: mp 112 °C (fusion); [α]23D −5.7° (c 0.53, CH3OH); 1H
NMR (300 MHz; CD3OD) δ 7.65 (br d, J = 6.0 Hz, 2H), 7.56−7.38
(m, 4H), 7.26 (d, J = 9.0 Hz, 2H), 7.20−7.06 (m, 3H), 6.93 (d, J = 9.0
Hz, 2H), 4.38−4.22 (m, 1H), 3.83−3.60 (m, 1H), 3.44−3.33 (m, 1H),
2.64 (d, J = 7.5 Hz, 2H), 2.54−2.42 (m, 1H), 1.85−1.60 (m, 4H),
1.50−1.16 (m, 4H), 1.03−0.93 (m, 6H), 0.87 (t, J = 6.0 Hz, 3H); 13C
NMR (75 MHz; CD3OD) δ 176.0, 143.8, 142.7, 142.0, 141.5, 138.4,
130.3, 129.8, 129.6, 129.5, 128.0, 127.5, 127.2, 57.0, 50.7, 38.7, 37.3,
28.1, 26.5, 26.0, 25.7, 17.9, 14.4, 14.2, 11.9; HRMS (ESI) calcd. for
C31H38N2O [M + H]+: 455.3057. Found: 455.3061.
ASSOCIATED CONTENT
■
S
* Supporting Information
Copies of HPLC results of 1−3, 4a−i, 5a−e, 6a, and 6b. This
material is available free of charge via the Internet at http://
pubs.acs.org.
AUTHOR INFORMATION
■
Corresponding Author
2-Pyridylacetic Acid [(2S,3S)-2-Amino-3-methylpentyl]-(4′-pro-
pylbiphenyl-4-yl)amide Dihydrochloride (6b). The procedure for 1
was followed using 90 mg (0.17 mmol) of 22b and 2 mL of 4 M HCl
in dioxane to give 80 mg (94%) of 6b as a white foam: 1H NMR (300
MHz; CD3OD) δ 8.76 (br d, J = 6.0 Hz, 1H), 8.41 (br t, J = 7.5 Hz,
1H), 7.92−7.50 (m, 8H), 7.30 (d, J = 6.0 Hz, 2H), 4.50−4.38 (m,
1H), 3.75−3.56 (m, 1H), 3.52−3.38 (m, 1H), 2.64 (d, J = 7.5 Hz,
2H), 1.90−1.60 (m, 3H), 1.50−1.15 (m, 2H), 1.02−0.90 (m, 6H),
0.84 (t, J = 6.0 Hz, 3H) (Methylene protons overlapped with
methanol solvent peak); 13C NMR (75 MHz; CDCl3) δ 169.6, 150.2,
146.5, 142.7, 142.2, 141.6, 139.2, 136.8, 129.6, 129.1, 128.9, 126.9,
125.4, 55.2, 48.9, 39.8, 37.7, 35.8, 26.2, 24.4, 14.2, 13.8, 11.4; HRMS
(ESI) calcd. for C28H35N3O [M + H]+: 430.2853. Found: 430.2860.
Pharmacology. Materials. Isoproterenol was purchased from
Sigma-Aldrich, and cell culture reagents (media, supplements,
antibiotics, etc.) were purchased from Fisher Scientific. Human
*Telephone: 919 541-6328. Fax: 919 541-8868. E-mail: cjin@
rti.org.
Funding
We thank the National Institute of Mental Health (NIMH) for
supporting the research at Psychoactive Drug Screening
Program (PDSP). XPZ is grateful for financial support by
NSF (CHE-1152767) and NIH (R01-GM098777).
Notes
The authors declare no competing financial interest.
ACKNOWLEDGMENTS
■
We thank Dr. Danni Harris for valuable discussions during the
course of this work.
K
dx.doi.org/10.1021/cn500082p | ACS Chem. Neurosci. XXXX, XXX, XXX−XXX

ACS Chemical Neuroscience
Research Article
(11) (a) Chen, Y., Fields, K. B., and Zhang, X. P. (2004)
Bromoporphyrins as versatile synthons for modular construction of
chiral porphyrins: cobalt-catalyzed highly enantioselective and
diastereoselective cyclopropanation. J. Am. Chem. Soc. 126, 14718−
14719. (b) Chen, Y., and Zhang, X. P. (2007) Asymmetric
cyclopropanation of styrenes catalyzed by metal complexes of D2-
symmetrical chiral porphyrin: superiority of cobalt over iron. J. Org.
Chem. 72, 5931−5934. (c) Chen, Y., Ruppel, J. V., and Zhang, X. P.
(2007) Cobalt-catalyzed asymmetric cyclopropanation of electron-
deficient olefins. J. Am. Chem. Soc. 129, 12074−12075. (d) Dzik, W. I.,
Xu, X., Zhang, X. P., Reek, J. N., and de Bruin, B. (2010) “Carbene
radicals” in Co(II)(por)-catalyzed olefin cyclopropanation. J. Am.
Chem. Soc. 132, 10891−10902. (e) Lu, H., Dzik, W. I., Xu, X., Wojtas,
L., de Bruin, B., and Zhang, X. P. (2011) Experimental evidence for
cobalt(II)-carbene radicals: key intermediates in cobalt(II)-based
metalloradical cyclopropanation. J. Am. Chem. Soc. 133, 8518−8521.
(12) Cheng, K., Lee, Y. S., Rothman, R. B., Dersch, C. M., Bittman, R.
W., Jacobson, A. E., and Rice, K. C. (2011) Probes for narcotic
receptor mediated phenomena. 41. Unusual inverse μ-agonists and
potent μ-opioid antagonists by modification of the N-substituent in
enantiomeric 5-(3-hydroxyphenyl)morphans. J. Med. Chem. 54, 957−
969.
(13) (a) Allen, J. A., Yost, J. M., Setola, V., Chen, X., Sassano, M. F.,
Chen, M., Peterson, S., Yadav, P. N., Huang, X. P., Feng, B., Jensen, N.
H., Che, X., Bai, X., Frye, S. V., Wetsel, W. C., Caron, M. G., Javitch, J.
A., Roth, B. L., and Jin, J. (2011) Discovery of β-arrestin-biased
dopamine D2 ligands for probing signal transduction pathways
essential for antipsychotic efficacy. Proc. Natl. Acad. Sci. U.S.A. 108,
18488−18493. (b) Besnard, J., Ruda, G. F., Setola, V., Abecassis, K.,
Rodriguiz, R. M., Huang, X. P., Norval, S., Sassano, M. F., Shin, A. I.,
Webster, L. A., Simeons, F. R., Stojanovski, L., Prat, A., Seidah, N. G.,
Constam, D. B., Bickerton, G. R., Read, K. D., Wetsel, W. C., Gilbert, I.
H., Roth, B. L., and Hopkins, A. L. (2012) Automated design of
ligands to polypharmacological profiles. Nature 492, 215−220.
(14) Wacker, D., Wang, C., Katritch, V., Han, G. W., Huang, X. P.,
Vardy, E., McCorvy, J. D., Jiang, Y., Chu, M., Siu, F. Y., Liu, W., Xu, H.
E., Cherezov, V., Roth, B. L., and Stevens, R. C. (2013) Structural
features for functional selectivity at serotonin receptors. Science 340,
615−619.
REFERENCES
■
(1) Mizushima, K., Miyamoto, Y., Tsukahara, F., Hirai, M., Sakaki, Y.,
and Ito, T. (2000) A novel G-protein-coupled receptor gene expressed
in striatum. Genomics 69, 314−321.
(2) (a) Ghate, A., Befort, K., Becker, J. A., Filliol, D., Bole-Feysot, C.,
Demebele, D., Jost, B., Koch, M., and Kieffer, B. L. (2007)
Identification of novel striatal genes by expression profiling in adult
mouse brain. Neuroscience 146, 1182−1192. (b) Massart, R., Guilloux,
J. P., Mignon, V., Sokoloff, P., and Diaz, J. (2009) Striatal GPR88
expression is confined to the whole projection neuron population and
is regulated by dopaminergic and glutamatergic afferents. Eur. J.
Neurosci. 30, 397−414. (c) Van Waes, V., Tseng, K. Y., and Steiner, H.
(2011) GPR88 - a putative signaling molecule predominantly
expressed in the striatum: Cellular localization and developmental
regulation. Basal Ganglia 1, 83−89. (d) Becker, J. A., Befort, K., Blad,
C., Filliol, D., Ghate, A., Dembele, D., Thibault, C., Koch, M., Muller,
J., Lardenois, A., Poch, O., and Kieffer, B. L. (2008) Transcriptome
analysis identifies genes with enriched expression in the mouse central
extended amygdala. Neuroscience 156, 950−965.
(3) Quintana, A., Sanz, E., Wang, W., Storey, G. P., Guler, A. D.,
Wanat, M. J., Roller, B. A., La Torre, A., Amieux, P. S., McKnight, G.
S., Bamford, N. S., and Palmiter, R. D. (2012) Lack of GPR88
enhances medium spiny neuron activity and alters motor- and cue-
dependent behaviors. Nat. Neurosci. 15, 1547−1555.
(4) Logue, S. F., Grauer, S. M., Paulsen, J., Graf, R., Taylor, N., Sung,
M. A., Zhang, L., Hughes, Z., Pulito, V. L., Liu, F., Rosenzweig-Lipson,
S., Brandon, N. J., Marquis, K. L., Bates, B., and Pausch, M. (2009)
The orphan GPCR, GPR88, modulates function of the striatal
dopamine system: a possible therapeutic target for psychiatric
disorders? Mol. Cell Neurosci. 42, 438−447.
(5) Lovinger, D. M. (2012) New twist on orphan receptor GPR88
function. Nat. Neurosci. 15, 1469−1470.
(6) Matsuoka, T., Tsunoda, M., Sumiyoshi, T., Takasaki, I., Tabuchi,
Y., Seo, T., Tanaka, K., Uehara, T., Itoh, H., Suzuki, M., and Kurachi,
M. (2008) Effect of MK-801 on gene expressions in the amygdala of
rats. Synapse 62, 1−7.
(7) (a) Ogden, C. A., Rich, M. E., Schork, N. J., Paulus, M. P., Geyer,
M. A., Lohr, J. B., Kuczenski, R., and Niculescu, A. B. (2004)
Candidate genes, pathways and mechanisms for bipolar (manic-
depressive) and related disorders: an expanded convergent functional
genomics approach. Mol. Psychiatry 9, 1007−1029. (b) Brandish, P. E.,
Su, M., Holder, D. J., Hodor, P., Szumiloski, J., Kleinhanz, R. R.,
Forbes, J. E., McWhorter, M. E., Duenwald, S. J., Parrish, M. L., Na, S.,
Liu, Y., Phillips, R. L., Renger, J. J., Sankaranarayanan, S., Simon, A. J.,
and Scolnick, E. M. (2005) Regulation of gene expression by lithium
and depletion of inositol in slices of adult rat cortex. Neuron 45, 861−
872.
(8) Conti, B., Maier, R., Barr, A. M., Morale, M. C., Lu, X., Sanna, P.
P., Bilbe, G., Hoyer, D., and Bartfai, T. (2007) Region-specific
transcriptional changes following the three antidepressant treatments
electro convulsive therapy, sleep deprivation and fluoxetine. Mol.
Psychiatry 12, 167−189.
(9) Befort, K., Filliol, D., Ghate, A., Darcq, E., Matifas, A., Muller, J.,
Lardenois, A., Thibault, C., Dembele, D., Le Merrer, J., Becker, J. A.,
Poch, O., and Kieffer, B. L. (2008) Mu-opioid receptor activation
induces transcriptional plasticity in the central extended amygdala. Eur.
J. Neurosci. 27, 2973−2984.
(10) (a) Bi, Y., Dzierba, C. D., Bronson, J. J., Carson, K., Cianchetta,
G., Dong, L., Fink, C., Green, M., Kimball, D., Macor, J. E., Kwon, S.,
Wang, J., Zhang, Y., Zipp, G. Modulators of G protein-coupled
receptor 88. U.S. Patent Application 2011/0245264, 2011;. (b) Bi, Y.,
Dzierba, C. D., Bronson, J. J., Fink, C., Green, M., Kimball, D., Macor,
J. E., Kwon, S., Zhang, Y., and Zipp, G. (2011) Modulators of G
protein-coupled receptor 88. U.S. Patent Application 2011/0251204.
(c) Dzierba, C. D., Hartz, R. A., Bi, Y., Ahuja, V. T., Bronson, J. J.,
Carson, K., Cianchetta, G., Green, M., Kimball, D., Kimura, S. R.,
Kwon, S., Macor, J. E., Zhang, Y., and Zipp, G. (2011) Modulators of
G protein-coupled receptor 88. U.S. Patent Application 2011/
0251196.
L
dx.doi.org/10.1021/cn500082p | ACS Chem. Neurosci. XXXX, XXX, XXX−XXX